WOAH standards related to VBDs: animal and vector surveillance

WOAH Regional Workshop on Vector Borne diseases in Asia and the Pacific

19-20 September 2024

Mauro Meske **WOAH Status Department**

Francisco D'Alessio **WOAH Standards Department**



World Organisation for Animal lealth

animale

Organisation mondiale Mundial de la santé Animal

Organización de Sanidad



WOAH international standards

WOAH establishes standards for the improvement of <u>animal</u> <u>health</u> and <u>welfare</u> and <u>veterinary public health</u> worldwide, including the <u>prevention of disease</u> <u>spread through</u> <u>international trade of</u> <u>animals and animal</u> <u>products</u>. Ensuring transparency and enhancing knowledge of the worldwide animal health situation.

Development of national policies and national sanitary systems



ξ

Assessment of potential trading partners and their health situation



WAHIS

Drafting of **import sanitary measures**, according to the commodity and their origin



Veterinary certification and export/import procedures




Terrestrial Code



Volume I User's guide and Horizontal chapters Volume II Disease-specific chapters

- New version every year
- Latest version publicly available on the WOAH website
- Previous editions are also available





Terrestrial Code - content

Volume I: Horizontal chapters

- User's Guide
- Glossary
- Animal disease diagnosis, surveillance and notification
- Risk analysis
- Quality of Veterinary Services
- Disease prevention and control
- Trade measures, import-export procedures and veterinary certification
- Veterinary public health
- Animal welfare

Volume II: Disease-specific chapters

- Definition of infection/ infestation and specific epidemiological considerations
- Safe commodities where appropriate
 - Safe commodities = based on absence of the pathogenic agent in the traded commodity OR inactivation by processing or treatment that the commodity has undergone
 - Importing countries should not apply trade restrictions to safe commodities with respect to the pathogenic agent concerned
- **Determination of the animal health status** of a country, zone or compartment
 - Official status recognition
 - Self declaration of animal health status

- Recommendations on safe trade for live animals, genetic material, other products of animal origin (meat, milk, eggs, skins, etc.)
- Specific management of commodities, e.g.
 - Recommendations on inactivation
 - Vector-protection during transport
- Recommendations on surveillance
 - Surveillance strategies specific to infection/ infestation
 - Link to Chapter 1.4 and 1.5 on animal health and vector surveillance



Glossary

Vector

means an insect or any living carrier that transports an infectious agent from an infected individual to a susceptible individual or its food or immediate surroundings. The organism may or may not pass through a development cycle within the vector.

Infestation

means the external invasion or colonisation of animals or their immediate surroundings by arthropods, which may cause clinical signs or are potential vectors of pathogenic agents.

Official control programme

means a programme which is approved, and managed or supervised by the Veterinary Authority of a Member Country for the purposes of controlling a vector, pathogenic agent or disease by specific measures applied throughout that Member Country, or within a zone or compartment of that Member Country.



SECTION 1. ANIMAL DISEASE DIAGNOSIS, SURVEILLANCE AND NOTIFICATION

Chapter 1.1.	Notification of diseases and provision of epidemiological information
Chapter 1.2.	Criteria for the inclusion in the OIE list
Chapter 1.3.	Diseases, infections and infestations listed by the OIE
Chapter 1.4.	Animal health surveillance
Chapter 1.5.	Surveillance for arthropod vectors of animal diseases

SECTION 4. DISEASE PREVENTION AND CONTROL

Chapter 4.4.	Zoning and compartmentalisation
Chapter 4.5.	Application of compartmentalisation
Chapter 4.18.	Official control programmes for listed and emerging diseases

Specific WOAH Standards

Terrestrial Code Chapter 1.5. Surveillance for arthropod vectors of animal diseases



Chapter 1.5. Article 1.5.1. Introduction

- The Terrestrial Code contains recommendations for the surveillance of several vector-borne diseases and general recommendations for animal health surveillance.
- The need has arisen to complement these general recommendations on surveillance with advice on the surveillance for vectors themselves. This chapter only addresses surveillance for arthropod vectors.

CHAPTER 1.5.

SURVEILLANCE FOR ARTHROPOD VECTORS OF Animal diseases

Introduction

Vector-bome diseases are of increasing importance economically and to human and animal health.

Environmental (including climate change), sociological and economical changes may affect the distribution and impact of these diseases.

sproved understanding of the distribution and population dynamics of the vectors is a key element for assessing and managing the risks associated with vector-borne animal and zoonotic diseases.

The Terrestrial Code contains recommendations for the surveillance of several vector-borne diseases and genera ecommendations for animal health surveillance.

he need has arisen to complement these general recommendations on surveilance with advice on the surveilance (sectors themselves. This chapter only addresses surveilance for arthropod vectors.

For the purpose of tasks, it should be noted that there is no conclusive relationship between the presence of vectors and the disease status of a country/zone, and also that the apparent absence of vectors does not by itself confirm vector-free status.

Article 1.5.2

A decision tree for vector surveillance is presented in Figure 1.

 For the purpose of trade, it should be noted that there is no conclusive relationship between the presence of vectors and the disease status of a country/zone, and also that the apparent absence of vectors does not by itself confirm vector-free status.

First adopted in 2009;

Most recent update adopted in 2010.



Chapter 1.5. Article 1.5.2. Objectives

 gathering up-to-date information on the spatial and temporal distribution and abundance of vectors of the arthropod-borne listed diseases and emerging diseases;

2) **monitoring changes** in the spatial and temporal distribution and abundance of these vectors;

3) collecting relevant data to **inform risk assessment** (including vector competency) and risk management of these vector-borne diseases;

4) detecting the presence of specific vectors or confirming their absence;
5) understanding pathways of entry for vectors and vector-borne pathogenic agents.

Article 1.5.3. Sampling methodology: Sampling methods- Data management, analysis and interpretation




WOAH Listed diseases & Vector borne – State of play

Multiple species (11/26)	Bovine (5/12)	Sheep & Goats (2/12)	Equine (5/11)	Swine (2/6)	None
Crimean Congo hemorrhagic fever Equine encephalomyelitis (Eastern) Heartwater	Bovine anaplasmosis	Infection with Theileria I	Equine encephalomyelitis (Western)		Avian
Infection with <i>T. bracei, T. congolense, T. simiae</i> and <i>T. vivax</i>	Bovine babesiosis	estoquardi, Theileria luwenshuni and Theileria uilenbergi	Equine infectious anaemia	Infection with African swine fever virus	Leporids
Infection with epizootic hemorrhagic disease virus Infection with Leishmania spp. (Leishmaniosis) Infection with Rift Valley fever	Enzootic bovine leukosis		Equine piroplasmosis		Bees
Virus Japanese encephalitis Surra (Trypanosoma evansi)	Infection with lumpy skin disease virus	Nairobi sheep disease	Infection with African horse sickness virus	Nipah virus encephalitis	(but tropilaelaps spp.; varroa spp. mites can act as vectors)
Tularemia West Nile fever	Infection with <i>Theileria</i> annulata, <i>Theileria</i> orientalis and <i>Theileria</i> parva		Venezuelan equine encephalomyelitis.		Camels
Adopted in	2024-2023 Terrestrial Code C	hapter exists Chapter under rev	ision In preparation		



Volume II: Diseasespecific chapters



Terrestrial Manual



- 1. Definition of infection/ infestation, its occurrence and specific epidemiological considerations (including relevant vectors)
- 2. Determination of the animal health status of a country, zone or compartment
- 3. Recommendations on safe trade for live animals, genetic material, other products of animal origin (meat, milk, eggs, skins, etc.)
- 4. Recommendations on surveillance

Complementary Chapters – Regularly updated


- 1. Standards for diagnosis and vaccines
- 2. Epidemiological information
- 3. Detailed information on vectors, vector species, etc



Specific considerations for VBD

1. Definition of disease occurrence

- Detection of the pathogenic agent in an animal (not vector)
- 2. Animal health Status
 - Vector Surveillance presence/absence of vector
 - Seasonal Freedom
 - High surveillance area bordering infected country or zone
- 3. Protection of animals from vectors
 - vector-protected establishment or facility
 - During transport
- 4. Vector related sanitary measures for trade
 - Free of ticks treatment
 - Protection from vector attacks during transport/transit





Using Terrestrial Code Standards on Vector Surveillance


Chapter 1.4.	Animal health surveillance
Chapter 1.5.	Surveillance for arthropod vectors of animal diseases

Chapter 4.4.	Zoning and compartmentalisation
Chapter 4.18.	Vaccination
Chapter 4.19.	Official control programmes for listed and emerging diseases

Chapter 1.6.Procedures for official recognition of AH status, by WOAHChapter 1.7.-1.12.Application for official recognition by WOAH of free status for ...

Volume II: Disease-specific chapters






Thank you

12, rue de Prony, 75017 Paris, France T. +33 (0)1 44 15 19 49 F. +33 (0)1 42 67 09 87

woah@woah.int www.woah.org

Facebook Twitter Instagram LinkedIn YouTube Flickr





World Organisation for Animal Health Founded as OIE

Organisation Organización mondiale Mundial de la santé animale Animal Fondée en tant qu'OIE

de Sanidad Fundada como OIE

WOAH Regional Workshop on Vector Borne diseases in Asia and the Pacific 19-20 September 2024

Updates on recent trends of VBDs Globally and in Asia Pacific reported to WOAH (2023-2024)

Mauro Meske Disease Status Officer <u>m.meske@woah.org</u>



 World
 Organisation

 Organisation
 mondiale

 for Animal
 de la santé


 Health
 animale

 Founded as OIE
 Fondée en tant qu'OIE


tion Organización Mundial é de Sanidad Animal

Paolo Tizzani Veterinary epidemiologist Data Integration Department






These maps show the predicted global ranges of Aedes aegypti (above) and Aedes albopictus (below) in 2050 assuming a 'medium' climate scenario in which greenhouse gas emissions peak in 2080 and then begin to decline. The darker areas have the highest predicted prevalence of mosquitos. MORITZ KRAEMER FOR NATURE MICROBIOLOGY






+11 million passengers fly everyday (IATA, 2020)

B. Global trade of live animals






4



Adopting a One Health approach


"Human health and animal health are interdependent and bound to the health of the ecosystems in which they exist."



Human Mobility and transport Population growth Healthcare systems



Phases of pathogen emergence & surveillance



Overview of Vector-Borne Diseases (VBDs)

- Importance: VBDs significantly impact both human and animal health globally
- Climate Change Impact: Alters vector density, activity periods, and geographical distribution, increasing the risk of VBD spread
- The transmission potential of these diseases is **also influenced by a range of factors**, including socio-economics, health-care capacity and ecology.

Reporting of VBDs in 2023-2024 -Key Statistics:

- Most frequently reported: West Nile Fever (12 notifications), Bluetongue (8), Lumpy Skin Disease (7), and Equine Infectious Anaemia (6).
- Geographical Spread: 28 countries reported 2,422 outbreaks, primarily in the Americas and Europe. Most of the outbreaks were concentrated in the Americas, with a very large event of Western equine encephalomyelitis (Western) (1,461 outbreaks), followed by Europe with 697 outbreaks, in this case reported for eight different VBDs.
- Lumpy skin disease was the most frequently reported VBD in Asia, with 144 outbreaks.







Relevant epidemiological changes in vector-borne diseases (91GS– Animal Health Situation)

- VBDs and Climate Change- Significant Observations:
- 99% of VBD outbreaks reported were in temperate regions.
- Increasing trend in the maximum latitude of VBD outbreaks, correlated with rising global temperatures.

Spatial distribution of outbreaks reported to WOAH for ten VBDs through immediate notifications and follow-up reports during 2023 and early 2024 (as of 8 March). The limits of the temperate regions (23.5° and 66.5° N/S of the Equator) are shown on the map:







Time series comparison of the maximum annual latitude at which outbreaks were reported and the global annual anomaly temperature detection for the period 2005–2023.

Case Study: Epizootic Haemorrhagic Disease (EHD)


- **Spread:** EHD has expanded from North America to new areas, including Europe since 2022. At a global level, 23 countries have reported the presence of the disease since 2009.
- **Recent Developments**: 252 new outbreaks reported in Europe across four countries since 2022.



Global spread of EHD up to 2024. The map categorises countries based



Evolution of countries reporting the presence of EHD during the period 2009–2024 (as of 8 March). Data for the different geographical regions are shown in the bar chart





Case Study from the Region: Outbreaks of Japanese Encephalitis (Australia)

- Outbreaks of Japanese encephalitis have been reported in piggeries in Queensland, New South Wales, Victoria and South Australia.
- Climate conditions of above median rainfall and warmer minimum temperature may have been a factor in the event.
- Spillover events into Humans and a case in an Alpaca
- Infection with JE virus in horses were not detected
- Trade restrictions for the movement of horses according to WOAH provisions triggered the revision of the JE Code Chapter




DISEASE DISTRIBUTION: Bluetongue- Data from WAHIS (2019-2024)






DISEASE DISTRIBUTION: Theileriosis (left above) & Bovine Anaplasmosis (below) – Data from WAHIS




part.

Iran




DISEASE DISTRIBUTION: West Nile Fever (left) & Western Equine Encephalomyelitis (right) -WAHIS






Global distribution of Surra (Trypanosoma evansi) (2019-2023)







DISEASE DISTRIBUTION - Data from the World Animal Health Information System (WAHIS)



Global distribution of African horse sickness



Global distribution of African horse sickness (2019-2023)



Key Takeaways:

Climate change is a major driver in the spread of VBDs

- Expanded Geographical Range
- Increased Vector Activity
- Unpredictable Outbreaks
- Correlation with Global Warming:

Recommendations

- Heightened Disease Surveillance
- Need for Global Collaboration
- Health and Economic Impacts

Continuous monitoring and adaptive strategies are crucial for effective VBD management.






Thank you

12, rue de Prony, 75017 Paris, France T. +33 (0)1 44 15 19 49 F. +33 (0)1 42 67 09 87 <u>m.meske@woah.org</u> <u>www.woah.org</u>

<u>Facebook</u> <u>Twitter</u> <u>Instagram</u> <u>LinkedIn</u> <u>YouTube</u> <u>Flickr</u>






Arbovirus infections of livestock animals in Asia:

what we know and don't know

Tohru Yanase Kagoshima Research Station, National Institute of Animal Health, NARO, Japan NARO

Arbovirus (<u>Arthropod-bo</u>rne virus)

- Arboviruses are transmitted by arthropod vectors via blood sucking process.
- Arboviruses replicate in both arthropod vectors and vertebrate hosts.
 - Arboviruses include many taxonomically different virus groups.



WOAH-listed arbovirus infections in Asia

Infection	Affected animal	Zoonosis	Endemic in Asia	Vector
Bluetongue	ruminants	No	Yes	Culicoides
Epizootic hemorrhagic disease	ruminants	No	Yes	Culicoides
African horse sickness	horse	No	No	Culicoides
Japanese encephalitis	pig, horse	Yes	Yes	mosquitos
Nairobi sheep disease	sheep	No	Yes	ticks
Crimean–Congo hemorrhagic fever	ruminants*	Yes	Yes	ticks
African swine fever	pig	No	Yes	ticks**

* Subclinical in most cases

** Highly contiguous between animals without ticks

We don't know the past and present status of the listed arbovirus infections in detail.

Due to

Lack of accurate information of affected animals, epidemiology, etiology and so on.....

Bluetongue (BT):

- Infection with BT virus and affecting ruminants
- High mortality rate in sheep of up to 70%
- Reported sporadic outbreaks in Asia

Epizootic hemorrhagic disease (EHD):

- Infection with EHD virus
- Severe clinical symptoms in white tailed deer and cattle
- Large outbreaks of Ibaraki disease with deglutition disorder in Japan
 - BT and EHD viruses have been circulating in Asia.
 - Multiple serotypes of these viruses are prevalent.

We don't know

How many animals are affected by both infections (no good statistical data). Which serotypes and/or strain has high virulent to domestic animals. Which vector species principally transmit the viruses in each region.

Not listed, but important arbovirus infections in Asia

Infection	Affected animal	Manifestations	Vector
Akabane disease	ruminants	abortion, premature birth, congenital malformations	Culicoides
Aino virus infection	ruminants	abortion, premature birth, congenital malformations	Culicoides
Chuzan disease	cattle	congenital malformations	Culicoides
Bovine ephemeral fever	cattle, water buffalo	cessation of lactation in dairy cattle, loss of condition in beef cattle	mosquito or <i>Culicoides</i>
Getah	horse, pig	fever, edema, rash (horse) reproductive disorders (pig)	mosquito

The causative viruses have been isolated/detected in Asian countries/regions.

These arbovirus infections have impacted livestock industry for many years.

The current status of these arbovirus infections are not shared in regional and global levels.

Akabane disease

Etiological agent: Akabane virus Genus: Orthobunyavirus

Symptoms:



Hydranencephaly

- Abortion, premature birth, still birth, congenital abnormalities (in utero infection)
- Encephalomyelitis (postnatal infection)

Affected hosts:

Cattle, water buffalo, sheep, goat

- In the past large outbreak, 42,000 cattle were affected in Japan, indicating Akabane disease has a high potentiality to impact livestock industry.
- Akabane virus is widely distributed in Asia, but there is a few report of affected animals from Asian countries and regions, except Japan.

Arboviruses potentially affecting livestock industry in Asia

Genus	Virus	Affected animal	Manifestations (suspected)	Vector
Orthobunyavirus	Peaton virus	cattle, sheep	abortion, congenital malformations	Culicoides
	Shamonda virus	cattle, goat	abortion, congenital malformations	Culicoides
	Sathuperi virus	cattle	congenital malformations	Culicoides
Orbivirus	D'Aguilar virus	cattle	congenital malformations	Culicoides

Orbiviruses recently identified in East Asia

Virus	Location of first detection in East Asia	Year of isolation	Vector	
EHDV serotype 5	Japan	2016	Culicoides	
EHDV serotype 6	Japan	2014		
EHDV serotype '10'	Japan	1998 (2017)		
EHDV YNDH/V079/2018	China	2018		
BTV serotype 29	China	2014		
BTV-X/XJ1407	China	2014		
Tibet orbivirus serotype 1	China	2009		
Tibet orbivirus serotype 2	China	2007		
Tibet orbivirus serotype 3	Japan	2009		
Tibet orbivirus serotype 4	Japan	2010		
Tibet orbivirus serotype 5	China	2019		
Tibet orbivirus serotype 6	China	2019		
Bunyip Creek virus	Japan	2008		
Marrakai virus	Japan	1997 (2024)		
Yunnan orbivirus	China	1999	mosquito	
Guangxi orbivirus	China	2015		
Yonaguni orbivirus	Japan	2014		

an outbreak of EHD in Japan in 2015


suspected association with neurological signs in cattle and sheep in Peru

EHD: epizootic hemorrhagic disease BT: bluetongue

Initially isolated in East Asia

Potential impact of neglected and emerging arboviruses

It is difficult to assess the impact of neglected and emerging arboviruses



Mutation

RNA viruses are characterized by high mutation rates.

Mutations may change pathogenicity, antigenicity, host range and competency of vectors.

A specific genotype of Akabane virus caused bovine encephalomyelitis by postnatal infection Porcine reproductive failures associated with Akabane virus were recently reported

Reassortment

- Related segmented viruses exchange genome segments in co-infected cells. The process is called "reassortment".
- Reassortment may change pathogenicity, antigenicity, host range and competency of vectors, drastically.

Orthobunyavirus

Genome: three segmented, negative-sense, single-stranded RNA

Akabane virus, Aino virus, Schmallenberg virus

Orbivirus

Genome: ten segmented, double-stranded RNA

Bluetongue virus, Chuzan virus, Epizootic hemorrhagic disease virus

Zoonotic arboviruses

Virus	Manifestations in human	Vector
Batai virus	mild flu-like illness	mosquito
Banna virus	encephalitis	mosquito
Japanese encephalitis virus	encephalitis	mosquito
SFTSV	severe fever with thrombocytopenia syndrome	tick
Crimean–Congo hemorrhagic fever virus	hemorrhagic fever	tick
Kyasanur forest disease virus	hemorrhagic fever	tick
Tick-borne encephalitis virus	encephalitis	tick

Several mosquito- and tick-borne viruses infect both human and livestock animals.

Livestock animal may play a role of amplifier for zoonotic arboviruses in some cases.

"Contribution" of livestock animals in transmission cycle of several zoonotic arboviruses remains uncertain.

Global warming

 Global warming may affect distribution, migration, phenology and competence of vectors.



Expansion of distribution range of arboviruses Changing epidemiology of arbovirus infections

Vector studies are not enough in Asian.

Little information


Principal vectors of each virus in each region

Biology of vector species

Assessment of vector competence by laboratory experiment

Outbreaks of Akabane disease in northern Japan

- Outbreaks of Akabane disease occurred in northern Japan in 2010 and 2022.
- The epizootic regions were out of historical range of known principal vector species.



Sero-conversion to Akabane virus in Japan in 2010 and 2022

Essential for future advancement

- Considering the impact of non-listed arbovirus infections (such as Akabane disease and bovine ephemeral fever)
- Risk assessment of neglected and emerging arboviruses
- Collaboration between public health and veterinary regions
- Information sharing with neighboring countries
- Constructing functional reporting systems for arbovirus infections
- Human resources development for arbovirus and vector researches
- Supports from our governments and WOAH

Thank you for your attention !!




Bluetongue virus

Update: Global and Regional and new advances in virus tracking

Dr Stacey Lynch

CSIRO Australian Centre for Disease Preparedness . WOAH Reference Laboratory for Bluetounge virus

WOAH Regional Workshop on VBDs in Asia and the Pacific | September 2024 Australia's National Science Agency







ACDP provides the highest levels of biocontainment within a purpose built biosecurity infrastructure to help protect Australia's livestock and aquatic industries, as well as people, from emerging infectious disease threats.

WOAH Reference Laboratory for Bluetounge virus : global ecology (esp. regional) inc. molecular epidemiology, improved diagnostics and surveillance strategies to support industry and trade.

- Dr Debbie Eagles, Director ACDP
- Dr Tristian Read, Veterinarian, ACDP

AAHL - Australia's national biocontainment facility







Bluetongue virus



The Disease

- Arbovirus Culicoides midges the primary vector
- A severe viral disease primarily affecting sheep, however infections also occur in cattle, goats and camelids
- WOAH-listed disease Important implications for trade
- Australia claims freedom from clinical bluetongue disease, however bluetongue virus transmission is common in northern NSW, QLD, NT and WA







- Dependent on host (species, breed), agent (serotype, strain) and environment
- Virus-mediated vascular injury
 - Oedema, hyperaemia, haemorrhage
- Sheep Morbidity up to 100% Mortality 0-30%
 - fever, excessive salivation, depression, dyspnoea, panting
 - clear nasal discharge (later mucopurulent)
 - tongue swollen, cyanotic
 - erosions/ulcerations in mouth
- Cattle, Goats, Camelids Morbidity < 5% and mortality rare







Source: WAHIS. Accessed 16-09-24. https://wahis.woah.org/#/dashboards/country-or-disease-dashboard





BTV ecology is changing and the Australian surveillance program



France

 BTV-4 and BTV-8 are considered endemic in France.

 France has recently reported on the emergence of a new strain of BTV-8 that appears to be more pathogenic

 French authorities reporting that current BTV-8 vaccines are effective

Figure 5: Phas strokings the departments in France affected by the recently energent taken of UFVA. Sink compressments the department is an above the rear structure of BTV in the resent state of the optimizer of the phase subscription and the real strurepresent the SSAm coastal area where windporce incomion would be likely. (Phis magers: oriented from data published by Plattern ESA sources at DHVD/SA, accessed 28 Weinstein 2023).







Europe – Historical situation (to 2018)

- Up until 1998, only sporadic BTV cases reported in Europe (Cyprus)
- 1998-2006 Various BTV serotypes spread into Mediterranean regions and became established
- 2006 BTV-8 outbreaks in Netherlands, Belgium, Germany, France and Luxembourg. Eradicated 2012 with mass vaccination.
- 2015 Re-emergence of BTV-8 in France, subsequent detections in Switzerland, Germany, Belgium and Spain



Global Update - Europe - 2023-2024

- 2023/24 Outbreaks of BTV-3 in North-Western Europe
- 2023 Emergence of a new strain of BTV-8 in France
- Expansion of distribution of BTV distribution in Spain
- New outbreaks in Italy



Australian context

- Bluetongue first detected in Australia, 1975, Northern Territory
- Have since detected a total of **12 serotypes**: 1, 2, 3, 5, 7, 9, 12, 15, 16, 20, 21, 23 and multiple genotypes (Seg-3)
- Historically free from clinical disease, but has significant implications for animal export
- Present in NT, WA, QLD, NSW with a seasonal distribution throughout
- Culicoides brevitaris the primary vector (also wadai, actoni, fulvis)
- Two 'episystems' with significant serotype & genetic diversity in NT, northern WA; less diversity in eastern Australia



National Arbovirus Monitoring Program (NAMP)

- Monitors the distribution of three economically important arboviruses and their vectors: Bluetongue virus, Akabane virus, bovine ephemeral virus
- Jointly funded (industry: government)

CSIRO

Multiple arbovirus surveillance strate




· Objectives: market access, early warning, risk management

Figure 2 Distribution of bluetongue virus in Australia, 2012-13 to 2014-15



https://animalhealthaustralia.com.au/maintaining-access-to-arbovirus-sensitive-markets/







Diagnostic Testing & Advances @ ACDP



- Family Reoviridae; genus Orbivirus
 - Related to African Horse Sickness virus
- ds RNA segmented genome
- 28⁺ serotypes
- <u>Segmented Genome 10 distinct</u> <u>segments. Gene reassortment</u> <u>known to occur.</u>








Gaps & Opportunities

Traditional testing does not:

- Inform a detailed understanding of transmission networks, as it is focussed on only 2/10 gene segments
- Provide spatio-temoporal context
- Consider the role of other gene segments in the epidemiology, and potentially, pathogenicity of BTV
 - Virulence determinants unknown likely associated with multiple gene segments

Determinant of serotype



Determinant of genotype




Recent developments at ACDP - genomics

- Developed a model that can perform fine-grained characterization of the genetic relationships between BTV isolates <u>at the whole genome level</u>.
 - To better understand the relationships between isolates
 - Spatio-temporal within Australia and outside of our country boarders
 - Potential future application to identifying virulence determinants
 - Can visualise this information (along with spatiotemporal data) in Nextstrain[®]





Nextstrain : now being applied for BTV in Australia




Map of possible global transmission pattern of SARS-CoV-2 clades from a subset of GISAID whole genome sequencing data. Source: Nextstrain

Whole Genome Sequencing and Nextstrain

- Greatly improves our understanding of the molecular epidemiology of BTV
 - Improved understanding of relationships between viruses to understand changes in virus transmission
 - Improved ability to detect:
 - recombination events
 - incursion & spread of exotic gene segments







Thank you

Dr Stacey Lynch Team Leader, Mammalian Infectious Disease Research

Stacey.Lynch@CSIRO.au

On behalf of the WOAH Reference Laboratory for Bluetounge virus https://animalhealthaustralia.com. au/maintaining-access-toarbovirus-sensitive-markets/

Maintaining access to arbovirus

sensitive markets

MAINTAINING ACCESS TO ARBOVIRUS SENSITIVE MAINETT

C EMERGENCY ANIMAL DISEASE

Q E

Share this page 🕢 🖪 🔘

animalhealth


Australia's National Science Agency



World Organisation for Animal Health Founded as OIE







EMERGENCE OH EPIZOOTIC HEMORRHAGIC DISEASE (EHD) IN EUROPE

STEPHAN ZIENTARA

ANSES - DIRECTOR OF ANIMAL HEALTH LABORATORY, FRANCE

EU/WOAH/FAO REFERENCE LAB ON FMD EU REFERENCE LAB ON EQUINE DISEASES WOAH REFERENCE LAB ON EHDV





Epizootic Haemorrhagic disease



0



Virology

Disease

Epidemiology


Diagnosis

Prevention

Orbivirus

0

Genus Orbivirus: 22 species



Bluetongue (BTV) & Epizootic Hemorrhagic Disease (EHD) WOAH & European notifiable animal diseases


BTV EHD\ Virus Sedoreoviridae, 36 serotypes 7 serotypes Orbivirus Susceptible Host(s) **III** "Reservoir" Bleeding + Inflammation Disease Fever, oedemas, loss of appetite, weakness, excessive salivation, haemorrhages, respiratory distress, ulceration (buccal mucosa, tongue...) **Transmission** Vector Culicoides Distribution Enzootic Emerging











Sedoreoviridae, Orbivirus







Figure from Rodríguez-Martín *et al.*, 2021

- Non-enveloped segmented dsRNA+ genome
- 10 segments ≈ 19,2 kb
- Conserved sequence at the extremities:
 - 5' [GUU(A/U)A(A/U) ... AC(A/U)UAC] 3'
- S1 to S8: Monocistronic segment
- S9 & S10: Bicistronic segments
- Serotyping: Segment 2

reassortment



EHDV caused by an Orbivirus Famille : Sedoreoviridae



EHDV Identity card




0509952018746NICOLAS<<PAUL<8206152M3

Grimes J.M., Burroughs J.N., Gouet P., Diprose J.M., Malby R., Zientara S., Mertens, P.P.C. & Stuart D.I. (1998). The atomic structure of the bluetongue virus core. *Nature*, 395, 470-478.









Although recognised earlier in the south-eastern United States,

EHD was first described after a severe outbreak of the disease in **white-tailed deer** (*Odocoileus virgininianus*) in New Jersey in 1955

Shope R.E., Macnamara L.G. & Mangold R. (1960). – A virusinduced epizootic hemorrhagic disease of the Virginia whitetailed deer (Odocoileus virginianus). J. Experim. Med., 111, 155– 170



Review

Epizootic haemorrhagic disease N.J. Maclachlan, S. Zientara, G. Savini & P.W. Daniels

Rev. Sci. Tech. Off. Int. Epiz., 2015, 34 (2), 341-351

Richard Edwin Shope


Richard Edwin Shope (1901-1966)



1924: instructor in pharmacology at the University of Iowa, studying tuberculosis, and rapidly joined the laboratories of the Rockefeller Institute at Princeton.



- **1928**: he left the field of tuberculosis to work on **hog cholera** and thus began a career in the field of **virology**.
- **1931**: identified swine influenza, together with his mentor Paul A. Lewis.
- 🔴 1932: rabbit fibroma.



"A new disease of deer"

...but

A VIRUS-INDUCED EPIZOOTIC HEMORRHAGIC DISEASE OF THE VIRGINIA WHITE-TAILED DEER (ODOCOILEUS VIRGINIANUS)*

BY RICHARD E. SHOPE, M.D., LESTER G. MACNAMARA, AND ROBERT MANGOLD

(From The Rockefeller Institute; and State of New Jersey Department of Conservation and Economic Development, Division of Fish and Game, Treuton)

> PLATES 7 TO 10 (Received for publication, September 22, 1959)

> > Shope RE (1960, J Exp Med)

"Among woodsmen and hunters in the South, the disease has long borne the name **"black tongue,"** presumably because one of the characteristics of a deer dead of it was a discolored and swollen tongue which generally protruded from the mouth. **Ruff**...has given a good description of "black tongue" (*Ruff FJ*; 1950 Wild Life in North Carolina)

WHAT IS "Black Tongue" AMONG DEER?

"we had been in **error** in our belief. Search of the **files** of the **United States Forest Service**... outbreaks of a fatal epizootic disease similar to the one we encountered in New Jersey have occurred in deer in various of the **southeastern states** at irregular intervals **at least since 1890***..."

"However, because this name has confusing connotations... we propose, therefore, to continue to designate the condition as epizootic hemorrhagic disease of deer (EHD)."

Damien Vitour

*Leonard E. Foote (Wild Life Management Institute; personal communication)

First reported epizootics of EHD



Ruff FJ (1950, Wild Life in North Carolina), Shope RE (1960, J Exp Med)





Virology

Disease

Epidemiology

Diagnosis

Prevention

Why Epizootic Haemorrhagic Disease of **DEER**?





Transmission by Culicoides sonorensis



Disease Transmission Cycle of Epizootic Hemorrhagic Disease (EHD)

other species

- C. insignis C. mohave
- C. debilipalpis
- C. obsoletus
- C. scoticus
- C. paraensis
- C. spinosus
- C. stellifer

...







• EHDV serotypes 1, 2, 6, 7 and 8 induce clinical signs in cattle

Epizootic haemorrhagic disease virus (EHDV) mainly infects deer, but sheep and cattle can also be infected.

EHDV added to the WOAH list in May 2008.

- · Loss of appetite
- Fear of humans lost
- Extensive haemorrhages
- Weakness
- · Excessive salivation
- Rapid pulse and respiratory rate
- Fever
- · Blue tongue from lack of oxygenated blood
- · Breaking of hooves caused by growth interruptions
- Diarrhoea
- Unconciousness
- Death




Virology

Disease


Epidemiology

Diagnosis

Prevention



Luis Jiménez-Cabello [®], Sergio Utrilla-Trigo, Gema Lorenzo, Javier Ortego [®] and Eva Calvo-Pinilla *[®]



EHDV-8



Epizootic Haemorrhagic Disease virus serotype 8 in Tunisia, 2021



Soufien Sghaier¹, Corinne Sailleau², Maurilia Marcacci³, Sarah Thabet¹, Valentina Curini³, Thameur Ben Hassine⁴, Liana Teodori³, Ottavio Portanti³, Salah Hammami⁵, Lucija Jurisic^{3,6}, Massimo Spedicato³, Lydie Postic², Ines Gazani⁷, Raja Ben Osman⁸, Stephan Zientara², Emmanuel Breard², Paolo Calistri³, Juergen A. Richt⁹, Edward C. Holmes¹⁰, Giovanni Savini³, Francesca Di Giallonardo¹¹, and Alessio Lorusso^{3*}



Figure 1. Clinical signs in cattle. (A) Teat erosions, (B) Oral congestion and erosions, (C) Submandibular oedema, conjunctivitis, and lacrimation, (D) Nasal discharge and mucosal erosion.

200 outbreaks





From 28 Octobre 2022

Clinical signs

- Cattle and a deer in Sardinia and Sicily (morbidity rate 5 to 10 %)
- Cattle in Andalusia (morbidity rate 10 to 15 %; mortality rate <1%)



Confirmation EHDV-8







EMERGING INFECTIOUS DISEASES°

EID Journal > Volume 29 > Number 5—May 2023 > Main Article

Volume 29, Number 5-May 2023


Research Letter

Epizootic Hemorrhagic Disease Virus Serotype 8, Italy, 2022

Alessio Lorusso , Stefano Cappai, Federica Loi, Luigia Pinna, Angelo Ruiu, Giantonella Puggioni, Annalisa Guercio, Giuseppa Purpari, Domenico Vicari, Soufien Sghaier, Stephan Zientara, Massimo Spedicato, Salah Hammami, Thameur Ben Hassine, Ottavio Portanti, Emmanuel Breard, Corinne Sailleu, Massimo Ancora, Daria Di Sabatino, Daniela Morelli, Paolo Calistri, and Giovanni Savini 28

The first infected animal






Alessio Lorusso, IZST





18 September 2023





Rechercher sur le site	Q
JE COMMANDE	

Accueil > Economie > Agriculture


Hautes-Pyrénées : détection d'un cas de maladie hémorragique épizootique (MHE) dans un élevage bovin



Pyrénées Atlantiques (2), Hautes Pyrénées (1) 18/09/2023







> Virologie (Montrouge). 2024 Feb 1;28(1):1-2. doi: 10.1684/vir.2024.1035.

Emergence of Epizootic Hemorrhagic Disease in France in 2023: Impacts and Future Prospects

Stéphan Zientara, Corinne Sailleau, Pascal Dujardin, Emmanuel Bréard, Damien Vitour



Dr Vivien Philis, Lannemezan Dr Mylène Lemaire-Meyer (LVD09)






Dr Alberto Jorda Blanco (Aude) Dr Mylène Lemaire-Meyer (LVD09)



29/01/24







June 2024


Confirmado el primer caso de enfermedad hemorrágica epizoótica de la actual temporada vectorial

El Ministerio de Agricultura, Pesca y Alimentación ha confirmado el primer caso de enfermedad hemorrágica epizoótica en una explotación de bovino de Guadalajara



Vacas libres de enfermedad hemorrágica epizodrica según la última actualización del Gobierno. (Foto: Freepik)





EHD 18 August 2024



Virology

Disease

Epidemiology

Diagnosis

Prevention


> Vet Ital. 2023 Dec 20. doi: 10.12834/VetIt.3433.23112.1. Online ahead of print.

Experimental infection of cattle, sheep, and goats with the newly emerged epizootic hemorrhagic disease virus serotype 8

Massimo Spedicato ¹, Francesca Profeta ¹, Sarah Thabet ², Liana Teodori ¹, Alessandra Leone ¹, Ottavio Portanti ¹, Maura Pisciella ¹, Barbara Bonfini ¹, Simone Pulsoni ¹, Francesca Rosso ¹, Emanuela Rossi ¹, Paola Ripà ¹, Angela De Rosa ¹, Eugenia Ciarrocchi ¹, Roberta Irelli ¹, Antonio Cocco ¹, Corinne Sailleu ³, Nicola Ferri ¹, Tiziana Di Febo ¹, Damien Vitour ³, Emmanuel Breard ³, Daniele Giansante ¹, Soufien Sghaier ⁴, Thameur Ben Hassine ⁵, Stephan Zientara ³, Romolo Salini ¹, Salah Hammami ², Giovanni Savini ¹, Alessio Lorusso ⁶

Affiliations + expand

PMID: 38117055 DOI: 10.12834/Vetlt.3433.23112.1



Α

В

6 calves, 4-5 months old, 2 males ; 4 females Strain EHDV-8, Sardinia 2022, 1 passage BSR cells 2 ml inoculum SC+ 1 ml ID, 6,7 log10 TCID50/ml

3/6: fever 1 calf: clinical signs

TERAMO

ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELL'ABRUZZO E DEL MOLISE "G. CAPORALE"

BT

Cattle

🖵 VI: 5-60 dd

🖵 RT-PCR: 5-180 dd

Sheep

🖵 VI: 5-30 dd


🖵 RT-PCR: 5-100 dd

Goats

□ VI: 5-30 dd □ RT-PCR: 5-100 dd



Viraemia



BT*≠***EHD**

G Savini



10/04/2024

Validated EHDV PCR

	KITS	FOURNISSEURs
	Méthode interne (LNR)	
Dépistage de groupe	ID Gene™ EHDV Duplex (id VET)	ID
« tout génotype »	VETMAX™ EHDV	Life Technologies SAS
(RT-PCR duplex)	Bio-T kit® EHDV	BioSellal
	ADIAVET™ EHDV REAL TIME	BioX
	ID Gene ™ EHDV Advantage Duplex	ID



Inactivated vaccine EHDV-8

Temporay authorization in France

Cattle


2 injections primo-vaccination.

Prevention of viremia (PCR >40) and reduction of clinical signs



➤ 190 outbreaks

22 August 2024



Acknowledgements







Corinne Sailleau



Mathilde Turpaud



Emmanuel Bréard







Giovanni Savini



Alessio Lorusso





Soufien Sghaier




Lydie Postic





Thank you for your attention





WOAH Regional Workshop on Vector Borne diseases in Asia and the Pacific

19-20 September 2024

LUMPY SKIN DISEASE

WOAH MANUAL: CHAPTER 3.4.12

Antoinette van Schalkwyk

Agricultural Research Council – Onderstepoort Veterinary Institute



Causative agent: [Poxvirus] - {Capripoxvirus}

- Lumpy skin disease virus

Type strain: Neethling strain (Western Cape, RSA, 1957)

<u>Ruminants</u>: Cattle and water buffalo.

<u>Wildlife</u>: Springbok, impala, eland, giraffe, camel, gazelle, oryx, Arabian oryx, banteng and Mainland searow

Notifiable disease: WOAH



Highly contagious viral infection

Vector-borne, non-zoonotic and transboundary disease

NOT an arbovirus

Require more investigations

Direct contact: Skin nodules, nasal discharge or saliva from infected animals

In-direct: Contaminated food, water and milk

Vertically: Intrauterine route

Long-distance dispersal of LSDV seems to occur via the movement of infected animals

Seasonal patterns indicate that arthropod-borne transmission (Mechanical): Blood-sucking or biting arthropods: Stable flies (*Stomoxys calcitrans*), Mosquitoes (*Aedes aegypti*), Hard ticks (*Rhipicephalus* and *Amblyomma* species) House fly (*Musca domestica*)



In 2022, isolation and characterisation of LSDV from a giraffe in a zoo was reported in Vietnam (Dao et al., 2022).

Namibia: an eland antelope (Taurotragus oryx), which was asymptomatic for LSD, but LSDV DNA isolated (Molini et al., 2021)

India: Farmed camels (Kumar et al., 2023)

India: Free living gazelle (Sundhankar et al., 2023) This evidence is supported by extensive serosurveys of wildlife in Africa which detected antibodies in very low numbers of samples (Davies, 1982; Hedger and Hamblin, 1983), leading the authors to conclude "wildlife in Africa probably does not play a very important part in the perpetuation and spread of LSDV".

LSDV has spread rapidly in recent years into the Middle East and Asia, and the susceptibility of wildlife species in these regions to LSDV is unknown.



In South Africa: Springbuck and giraffe - National parks and game reserves

Require more investigations





Lumpy skin disease: Global spread




South Africa: 1944

Kenya: 1958


Middle East: 1988 and again in 2006

Europe, Caucus and Russia: 2015

China and India: 2019



Lumpy skin disease: Epidemiology



Lumpy skin disease: Phylogenetics

Clusters 1.1 and 1.2

LSDVs representing sequences from both clusters were circulating in Africa in the 1950's.

Majority of the DIVA assays are based on differentiation between cluster 1.1 and 1.2. Thus not suitable to detect the field isolates of cluster 1.1 ± 2,200 SNPs between cluster 1.1 and 1.2 (Kara et al., 2003; van Schalkwyk et al., 2021)

- ± 1860 SNPs in 114 ORFs
- 57% Synonymous
- 26% Non-Synonymous
- ± 330 (15%) IGR

TMRCA: ± 500 years

100	KX764644 LSDV Herbivac vaccine MG972412 LSDV Cro2016 Croatia 2016 KX764643 LSDV SIS-Lumpyvax vaccine AF409138 LSDV Neethling vaccine LW 1959 KX764645 LSDV OBP vaccine MK441838 LSDV Herbivac LS-batch-008 vaccine OM793609 LSDV Vaccine LW-1959 1988 MW656252 LSDV Haden RSA 1954 OM793608 LSDV Neethling-WC RSA 1957 OM793606 LSDV Potter RSA 1958 OM793607 LSDV Fourie-FS RSA 1959 OM793605 LSDV Hoffmeyer RSA 1958 OM793604 LSDV 33-KZN RSA 1977 MN636839 LSDV 103-GP RSA 1991 MN636843 LSDV 148-GP RSA 1993 MN636840 LSDV 248-NW RSA 1993 MN636841 LSDV 220-1-NW RSA 1993 MN636842 LSDV 220-2-NW RSA 1993	LSDV Cluster 1.1
 AF325528 LSI AF409137 LS MW656253 LS MH893760 LS KY829023 LS MT643825 LS KY702007 LS KX894508 LS MN642592 LS	DV KSGPO-240 Kenya 1959 DV NI-2490 Kenya 1958 DV Warmbaths-LW RSA 2000 SDV 280-KZN RSA 2018 SDV Neethling Russia 2015 DV Evros Greece 2015 DV 210-249 Bulgaria 2016 DV Bujanovac Serbia 2016 SDV Pendik Turkey 2014 DV Neethling 155920 Israel 2012 SDV Kubash Kazakhstan 2016 DV Neethling-RIBSP vaccine	LSDV Cluster 1.2

Goatpox virus

Sheeppox virus

100

Lumpy skin disease: Phylogenetics (Cluster 1.1)

Oldest isolate: Haden / 1954 (van Schalkwyk et al., 2021)

Prototype: Neethling-WC / 1957 (Alexander et al., 1957; van Schalkwyk et al., 2022)

Vaccine: Neethling LW1959 (van Rooyen et al., 1959;
 Kara et al., 2003)

Vaccine: OBP, Herbivac,
 SIS-Lumpyvax (Mathijs et al., 2016; Douglass et al., 2019)

Wild type field isolates: South Africa 1950's, 1970's and 1990's (van Schalkwyk et al., 2020 and 2022)

Cluster 1.1 - Attenuation Seven SNPs between Neethling-WC/1957 and Neethling-LW1959 vaccine (van Schalkwyk et al., 2022) Non-synonymous: LW028 T135A \bigcirc LW083: K663N Ο LW098: G553S \bigcirc

o LW098: I625T

Reading frame:
 LW086: Termination
 LW131: Termination
 LW134: Termination

0,000050

KX764643 LSDV SIS-Lumpyvax vaccine MG972412 LSDV Cro2016 Croatia 2016 KX764644 LSDV Herbivac vaccine KX764645 LSDV OBP vaccine MK441838 LSDV Herbivac LS-batch-008 vaccine - AF409138 LSDV Neethling vaccine LW 1959 OM793609 LSDV Vaccine LW-1959 1988 MW656252 LSDV Haden RSA 1954 OM793608 LSDV Neethling-WC RSA 1957 OM793606 LSDV Potter RSA 1958 OM793607 LSDV Fourie-FS RSA 1959 OM793605 LSDV Hoffmeyer RSA 1958 OM793604 LSDV 33-KZN RSA 1977 MN636839 LSDV 103-GP RSA 1991 MN636843 LSDV 148-GP RSA 1997 MN636838 LSDV 58-LP RSA 1993 MN636840 LSDV 248-NW RSA 1993 ⁹⁷ MN636841 LSDV 220-1-NW RSA 1993 MN636842 LSDV 220-2-NW RSA 1993



Lumpy skin disease: Phylogenetics (Cluster 1.2)

the first


Isolate: 2490/Kenya/1958 (Tulman et al., 2000)

Vaccine: KSGPO-240/1959 (Vandenbussche et al., 2016)

Vaccine: KSGPO-240/1959. Outbreak in Bangladesh, India, Nepal and Pakistan

Isolates from southern Africa 2000 – 2022 (Kara et al., 2003)

Isolates from Middle East, Europe and Asia 2012 – 2016



LSDV LD008 MP GP RSA 2022 LSDV LD032 GP RSA 2022 - LSDV LD028 GP RSA 2022 LSDV LD001 GP RSA 2021 LSDV LD004 GP RSA 2021 LSDV D2366 FS RSA 2011 LSDV LD260 NW 2017 MT007950 LSDV Neethling 9F Namibia 2016 MT007951 LSDV Neethling 10F Namibia 2016 MW656253 LSDV 280-KZN RSA 2018 AF409137 LSDV Warmbaths-LW RSA 2000 KY702007 LSDV Bujanovac Serbia 2016 KY829023 LSDV Evros Greece 2015 MT643825 LSDV 210-249 Bulgaria 2016 MH893760 LSDV Neethling Russia 2015 KX894508 LSDV Neethling 155920 Israel 2012 MN642592 LSDV Kubash Kazakhstan 2016 MN995838 LSDV Pendik Turkey 2014 OK318001 LSDV V281 Nigeria 2018 MW883897 LSDV Ranchi India 2019 MN072619 LSDV Kenya AF325528 LSDV NI-2490 Kenya 1958 ³³¹ KX683219 LSDV KSCPC 240 Konvo 1050



Lumpy skin disease

Parental sequences are both vaccines: - Neethling-LW1959 - KSGPO-240

Recombinants

2.1: Saratov/Russia/2017 (Sprygin et al., 2018)

2.2: Udmurtya/Russia/2018 (Sprygin et al., 2018)

2.3: Kostanay/Kazakhstan/2018

2.4: Tyumen/Russia/2019 (Krotova et al., 2022)

2.5: GD01/China/2019 (Ma et al., 2021)

2.6: Kurgan/Russia/2018 (Sprygin et al., 2024)

AF409138 LSDV Neethling-Vaccine LW195	59						
MW435866 LSDV Neethling-Vaccine LW19							
98 MH646674 LSDV Saratov Russia 2017							
OM530217 LSDV Saratov Russia 2019							
OL542833 LSDV Tyumen Russia 2019							
₉₂ MW732649 LSDV HongKong 2020							
MZ577073 20L42 Quyet-Thang VietNam 2020							
OM793603 LSDV Khabarovsk Russia 2020							
OM793602 LSDV Tomsk Russia 2020							
⁸⁴ 100 MW355944 GD01 China 2020							
MZ577074 20L43 Ly-Quoc VietNam 2020							
MZ577075 20L70 Dinh-To VietNam 2020							
MZ577076 20L81 Bang-Thanh VietNam 2020							
🚥 🖳 LSDV Kurgan Russia 2018							
MT992618 LSDV Kostanay Kazakhstan 2018							
MT134042 LSDV Udmurtya Russia 2018							
AF325528 LSDV NI-2490 Kenya 1958							
KX683219 LSDV KSGPO-240 Kenya 1959							

Excellence in Research and Developmen

Recombinants


The Importance of Quality Control of LSDV Live Attenuated Vaccines for Its Safe Application in the Field

```
by ⑧ Andy Haegeman <sup>1,*</sup> ⊠<sup>®</sup>, ⑧ Ilse De Leeuw <sup>1</sup> ⊠, ⑧ Meruyert Saduakassova <sup>2</sup> ⊠,
⑧ Willem Van Campe <sup>3</sup> ⊠, ⑧ Laetitia Aerts <sup>4</sup> ⊠, ⑧ Wannes Philips <sup>4</sup> ⊠, ⑧ Akhmetzhan Sultanov <sup>2</sup> ⊠,
⑧ Laurent Mostin <sup>3</sup> ⊠ and ⑧ Kris De Clercq <sup>1</sup> ⊠ <sup>©</sup>
```

Recombinant LSDV Strains in Asia: Vaccine Spillover or Natural Emergence?

Contaminated LSD vaccine = Neethling, KSPG vaccine and GTPV





Lumpy skin disease

Russia: Saratov & Udmurtiya

Non-vector-borne transmission of lumpy skin disease virus

Kononov Aleksandr¹, Byadovskaya Olga¹, Wallace B. David^{2,3}, Prutnikov Pavel¹, Pestova Yana¹, Kononova Svetlana¹, Nesterov Alexander¹, Rusaleev Vladimir¹, Lozovoy Dmitriy¹ & Sprygin Alexander¹ A lumpy skin disease virus which underwent a recombination event demonstrates more aggressive growth in primary cells and cattle than the classical field isolate

Svetlana Kononova¹ | Aleksandr Kononov¹ | Irina Shumilova¹ | Olga Byadovskaya¹ | Alexander Nesterov¹ | Pavel Prutnikov¹ | Shawn Babiuk² | Alexander Sprygin¹

Experimentally controlled study indicates that the naturally occurring recombinant vaccine-like lumpy skin disease strain Udmurtiya/2019, detected during freezing winter in northern latitudes, is transmitted *via* indirect contact

Alexander Nesterov¹, Ali Mazloum¹, Olga Byadovskaya¹, Irina Shumilova¹, Antoinette Van Schalkwyk^{2,3}, Alena Krotova¹, Vladimir Kirpichenko⁴, Irina Donnik⁵, Ilya Chvala¹ and Alexander Sprygin^{1*} Overwintering of recombinant lumpy skin disease virus in northern latitudes, Russia

Irina Shumilova¹ | Alena Krotova¹ | Alexander Nesterov¹ | Olga Byadovskaya¹ Antoinette van Schalkwyk² | Alexander Sprygin¹

Recombinants: Novel phenotypes

- Transmission
- Overwintering
- Aggressive growth



Phylogenetic analysis shows the majority of LSDV strains group into two monophyletic clusters (cluster 1.1 and 1.2) (Biswas et al., 2020; Van Schalkwyk et al., 2021). Cluster 1.1: Neethling Prototype Cluster 1.1 consists of LSDV Neethling vaccine strains that are based on the strain and vaccine LSDV/Neethling/WC-1957 type-strain (Kara et al., 2003; Van Rooyen et al., 1959; van Schalkwyk et al., 2020) and historic wild-type strains from South Africa. Cluster 1.2: Cluster 1.2 consists of wild-type strains from southern Africa, Kenya, the northern KSGP and "wild hemisphere, and the Kenyan KSGP O-240 commercial vaccine. type" In addition to these two clusters, there have recently been recombinant LSDV strains Cluster 2.1 -2.6: isolated from clinical cases of LSD in the field in Russia and central Asia (Flannery et al., Six unique 2021; Sprygin et al., 2018; 2020; Wang et al., 2021). These recombinant viruses show recombinant strains unique patterns of accessory gene alleles, consisting of sections of both wild-type and "vaccine" LSDV strains.



Laboratory confirmation:

- "Gold standard" serological test: serum/virus neutralization test (SNT/VNT).
 Not all animals either naturally infected or vaccinated develop LSDV neutralizing antibodies.
- Enzyme-linked immunosorbent assay (ELISA) by IDVet (France).
- Conventional and Real-Time Polymerase chain reaction (PCR) assays.
- Virus isolation on cell culture (Skin nodules).



Lumpy skin disease: WOAH Manual: B. DIAGNOSTIC TECHNIQUES

Kov		Purpose										
Key: +++ = recommended for this purpose	Method	Population freedom from infection	Individual animal freedom from infection prior to movement		Confirmation of clinical cases	Prevalence of infection – surveillance	Immune status in individual animals or populations post-vaccination					
	Detection of the agent											
++ recommended but has limitations	Virus isolation	+	++	+	+++	+	_					
	PCR	++	+++	++	+++	+	_					
+ = suitable in very limited circumstances	Transmission electron microscopy	_	_	—	+	—	—					
	Detection of immune response											
 – = not appropriate for this purpose 	VNT	++	++	++	++	++	++					
	IFAT	+	+	+	+	+	+					
	ELISA	++	++	++	++	++	++					

PCR = polymerase chain reaction; VNT = virus neutralisation test;

IFAT - indirect fluereceast antibady test. FLICA - ensure linked in revenue carbont eccay

Lumpy skin disease: Molecular test to differentiate vaccine and wild-type LSDV

DIVA: Differentiation of Infected from Vaccinated Animals

<u>CAN</u> **d**ifferentiate between cluster 1.1 and 1.2.

CAN NOT differentiate between vaccine and wild type isolates within Cluster 1.1

<u>CAN NOT</u> differentiate between vaccines and novel recombinant strains (Cluster 2.1 – 2.5) Quantitative real-time PCR assays have been designed to differentiate the "Neethling response" caused by vaccination with a Neethling-based LSDV strains and wild-type LSDV strains from cluster 1.2 (Agianniotaki et al., 2017; Pestova et al., 2018; Vidanovic et al., 2016).

However, they cannot distinguish between a LSDV Neethling vaccine strain and the novel recombinant LSDV strains recently isolated from disease outbreaks in Asia (Byadovskaya et al., 2021; Flannery et al., 2021). These DIVA assays are also not capable of discriminating between LSDV Neethling vaccine strains and recently characterised (historic) wild-type viruses from South Africa belonging within cluster 1.1 (Van Schalkwyk et al., 2020; 2021).

MG972412 LSDV Cro2016 Croatia 2016 H KX764643 LSDV SIS-Lumpyvax vaccine H AF409138 LSDV Neethling vaccine LW 1959 H KX764645 LSDV OBP vaccine H MK441838 LSDV Herbivac LS-batch-008 vaccine H OM793609 LSDV Vaccine LW-1959 1988 H OM793608 LSDV Neethling-WC RSA 1957 H OM793606 LSDV Potter RSA 1958 H OM793605 LSDV Hoffmeyer RSA 1959 H OM793604 LSDV 33-KZN RSA 1977 HN636839 LSDV 103-GP RSA 1991 MN636843 LSDV 148-GP RSA 1997 H	ж 1.1
AF409138 LSDV Neethling vaccine LW 1959 KX764645 LSDV OBP vaccine MK441838 LSDV Herbivac LS-batch-008 vaccine OM793609 LSDV Vaccine LW-1959 1988 MW656252 LSDV Haden RSA 1954 OM793608 LSDV Neethling-WC RSA 1957 OM793606 LSDV Potter RSA 1958 OM793607 LSDV Fourie-FS RSA 1959 OM793605 LSDV Hoffmeyer RSA 1958 OM793604 LSDV 33-KZN RSA 1977 MN636839 LSDV 103-GP RSA 1991 MN636843 LSDV 148-GP RSA 1997	۲ ۲ 1.1
KX764645 LSDV OBP vaccine MK441838 LSDV Herbivac LS-batch-008 vaccine OM793609 LSDV Vaccine LW-1959 1988 MW656252 LSDV Haden RSA 1954 OM793608 LSDV Neethling-WC RSA 1957 OM793606 LSDV Potter RSA 1958 OM793607 LSDV Fourie-FS RSA 1959 OM793605 LSDV Hoffmeyer RSA 1958 OM793604 LSDV 33-KZN RSA 1977 MN636839 LSDV 103-GP RSA 1991 MN636843 LSDV 148-GP RSA 1997	er 1.1
MK441838 LSDV Herbivac LS-batch-008 vaccine MK441838 LSDV Herbivac LS-batch-008 vaccine 0M793609 LSDV Vaccine LW-1959 1988 MW656252 LSDV Haden RSA 1959 MW656252 LSDV Haden RSA 1954 OM793608 LSDV Neethling-WC RSA 1957 OM793606 LSDV Potter RSA 1958 OM793607 LSDV Fourie-FS RSA 1959 OM793605 LSDV Hoffmeyer RSA 1958 OM793604 LSDV 33-KZN RSA 1977 MN636839 LSDV 103-GP RSA 1991 MN636843 LSDV 148-GP RSA 1997	9r 1.1
OM793609 LSDV Vaccine LW-1959 1988 MW656252 LSDV Haden RSA 1954 OM793608 LSDV Neethling-WC RSA 1957 OM793606 LSDV Potter RSA 1958 OM793607 LSDV Fourie-FS RSA 1959 OM793605 LSDV Hoffmeyer RSA 1958 OM793604 LSDV 33-KZN RSA 1977 MN636839 LSDV 103-GP RSA 1991 MN636843 LSDV 148-GP RSA 1997	ır 1.1
MW656252 LSDV Haden RSA 1954 OM793608 LSDV Neethling-WC RSA 1957 OM793606 LSDV Potter RSA 1958 OM793607 LSDV Fourie-FS RSA 1959 OM793605 LSDV Hoffmeyer RSA 1958 OM793604 LSDV 33-KZN RSA 1977 MN636839 LSDV 103-GP RSA 1991 MN636843 LSDV 148-GP RSA 1997	er 1.1
OM793608 LSDV Neethling-WC RSA 1957 OM793606 LSDV Potter RSA 1958 OM793607 LSDV Fourie-FS RSA 1959 OM793605 LSDV Hoffmeyer RSA 1958 OM793604 LSDV 33-KZN RSA 1977 MN636839 LSDV 103-GP RSA 1991 MN636843 LSDV 148-GP RSA 1997	er 1.1
OM793606 LSDV Potter RSA 1958 LSDV Cluster OM793607 LSDV Fourie-FS RSA 1959 OM793605 LSDV Hoffmeyer RSA 1958 OM793604 LSDV 33-KZN RSA 1977 MN636839 LSDV 103-GP RSA 1991 MN636843 LSDV 148-GP RSA 1997	er 1.1
OM793607 LSDV Fourie-FS RSA 1959 OM793605 LSDV Hoffmeyer RSA 1958 OM793604 LSDV 33-KZN RSA 1977 MN636839 LSDV 103-GP RSA 1991 MN636843 LSDV 148-GP RSA 1997	er 1.1
OM793605 LSDV Hoffmeyer RSA 1958 OM793604 LSDV 33-KZN RSA 1977 MN636839 LSDV 103-GP RSA 1991 MN636843 LSDV 148-GP RSA 1997	
OM793604 LSDV 33-KZN RSA 1977 MN636839 LSDV 103-GP RSA 1991 MN636843 LSDV 148-GP RSA 1997	
MN636839 LSDV 103-GP RSA 1991 MN636843 LSDV 148-GP RSA 1997	
MN636843 LSDV 148-GP RSA 1997	
MN636838 LSDV 58-LP RSA 1993	
¹⁰⁰ MN636840 LSDV 248-NW RSA 1993	
100 MN636841 LSDV 220-1-NW RSA 1993	
MN636842 LSDV 220-2-NW RSA 1993	
98 MH646674 LSDV Saratov Russia 2017 ISDV Recon	nbinant
100 MW355944 GD01 China 2020 ILSDV Recon	nbinant
MT992618 LSDV Kostanay Kazakhstan 2018] LSDV Recon	nbinant
MT134042 LSDV Udmurtya Russia 2018] LSDV Recon	nbinant
¹⁰⁰ 00 KX683219 LSDV KSGPO-240 Kenya 1959	
AF325528 LSDV NI-2490 Kenya 1958	
AF409137 LSDV Warmbaths-LW RSA 2000	
100 MW656253 LSDV 280-KZN RSA 2018	
MH893760 LSDV Neethling Russia 2015	
L KY829023 LSDV Evros Greece 2015	r 1 2
MT643825 LSDV 210-249 Bulgaria 2016	, I.Z
KY702007 LSDV Bujanovac Serbia 2016	
¹⁰⁰ MN995838 LSDV Pendik Turkey 2014	
KX894508 LSDV Neethling 155920 Israel 2012	
MN642592 LSDV Kubash Kazakhstan 2016	
MT130502 LSDV Neethling-RIBSP vaccine	
100 Goatpox virus	
■ Sheeppox virus	

Lumpy skin disease: New Markers

Kumar et al., 2023

HRM-based gap-qRT-PCR: 801bp in terminal repeat region (ITR)

Vaccine: (Lumpi-ProVac^{Ind}) vs. Wild type: (LSDV/2019/India/Ranchi)

Haegeman et al., 2023

Duplex qRT-PCR: LW133 and LW144

• Vaccine (Neethling) vs. Wild type: Cluster 1.2 vs. Recombinant (Cluster 2.5)

Krotova et al., 2023

PCR and Sanger sequencing: 705bp in ORF LW134

 Vaccines (Neethling and KSGPO) vs. Wild type Cluster 1.2 vs. Recombinant (Cluster 2.1, 2.2, 2.3, 2.4 and 2.5)



Nan et al., 2023	Triplex real-time PCR: • LSDV vs GTPV vs SPPV
Liao et al., 2023	CRISPR-Cas12a: • LSDV vs GTPV vs SPPV
Nandi et al., 2023	Isothermal PCR: 27bp in ORF LW126 • Vaccines (GTPV) vs. Wild type Cluster 1.2-KSGPO
Abdalhamed et al., 2022	Gold nanoparticle – lateral flow test
Sthitmatee et al., 2023	In-house ELISA using whole virus (LSD/THA/CMU/21/05)



Lumpy skin disease: WOAH Manual: C. REQUIREMENTS FOR VACCINES


Homologous vaccines: Attenuated LSDV (Neethling and KSGPO)

NO DIVA



Goatpox (Gorgan / Uttarkashi) Sheeppox (NISHKI)

Haegeman et al., 2023; Hamdi et al., 2020; Wolf et al., 2022



Homologous inactivated vaccines: Safe, regular boosters; <1 year immunity

New vaccines: vector-, subunit, mRNA vaccines



<u>DIVA</u>

Lumpy skin disease: Available vaccines

Titre, Dose, **Product Name and Virus** Manufacturer **Target Species** Strain Administration **Onderstepoort Biological** 10^{3.5}TCID₅₀/dose Lumpy Skin Disease Products (OBP) Vaccine for Cattle 2 ml SC (LSD Neethling strain) South Africa 10^{4.0}TCID₅₀/dose Intervet (Pty) South Lumpyvax[™] Vaccine for Cattle (LSD SIS Neethling strain) Africa/MSD Animal Health 2 ml SC 10^{3.5}TCID₅₀/dose Bovivax-LSD[™] MCI Santé Animale Vaccine for Cattle (LSD Kenya strain) 2 ml SC Morocco Jordan Bio-Industries LumpyShield-N[™] 10^{4.0}TCID₅₀/dose Center (JOVAC) Vaccine for Cattle 2 ml SC (LSD Neethling strain) Jordan Jordan Bio-Industries Caprivac[™] Center (JOVAC) Vaccine for Cattle (Gorgan GTP strain) Jordan Middle East for Vaccines 10^{3.5}TCID₅₀/dose **MEVAC LSD** (MEVAC) Vaccine for Cattle (LSD Neethling strain) 2 ml SC Egypt National Veterinary Institute Lumpy Skin Disease vaccine 10^{3.0}TCID₅₀/dose (NVI) Vaccine for Cattle (LSD Neethling strain) 2 ml SC Ethiopia Kenya Veterinary Vaccines Lumpivax™ Not known TCID₅₀/dose **Production Institute** Vaccine for Cattle (LSD Neethling strain) 2 ml SC (KEVEVAPI) Penpox-M[™] Pendik Veterinary Control 10^{2.5}TCID₅₀/dose Institute/ Ministry of Live SPPV Vaccine for Cattle 2 ml SC (Bakirköy SPPV strain) Agriculture, Turkey Poxvac[™] 10^{2.5}TCID₅₀/dose Vaccine for Sheep and Cattle (Bakirköy SPPV strain) Vetal Company 2 ml SC 10^{3.5}TCID₅₀/dose Turkey Lumpyvac[™] Vaccine for Cattle (LSD Neethling strain) 2 ml SC Poxdoll™ 10^{2.5}TCID₅₀/dose Vaccine for Sheep, goats and Cattle 2 ml SC Dollvet (Bakirköy SPPV strain) 10^{3.5}TCID₅₀/dose Turkey LSD-NDOLL Vaccine for Cattle (LSD Neethling strain) 2 ml SC FGBI-Federal Centre for Sheep Pox Cultyral Dry[™](Arriah (NISHKI) SPPV Animal Health Not known TCID₅₀/dose Vaccine for Sheep and Cattle Russia strain) ABIC, RM 65 Sheeppox (Yugoslavia Vaccine for Sheep and Cattle RM65) Israel

Tuppurainen et al., 2021

Lumpy skin disease: Vaccine testing (literature study by Pravesh Kara)

												_				
Breed Age Gender	Construct / Vaccine Dose Route & Volume	Number of animals	Fever (%)	Start of fever (Ave Days)	Inoculation site reaction (%)	>1 nodule (%)	Clinical reaction [other than fever] (%)	Shedding (PCR) (%)	Nodule (PCR) (%)	Viremia (PCR / VI) (%)	VNT 1 (%)	VNT 2 (%)	ELISA (%)	ірма (%)	ifit/ifat (%)	Reference
Holstein - Friesen 6 months Male	LSD Neethling OBP [1.4x10 ⁷ TCID ₅₀] SC Route: 2ml	5	0/5 (0%)	N/A	1/5 (20%)	0/5 (0%)	1/5 (20%)	Nd	0/1 (0%)	PCR 0/5 VI 0/5	0/5 (0%)	nd	nd	nd	nd	Kara et al., 2018
	LSD Neethling OBP [1x10 ^{3.5} TCID ₅₀] SC Route: 2ml	7	6/7 (86%)	days)	0/7 (0%)	0/7 (0%)	0/7 (0%)	Nd	0/7 (0%)	0/7 (0%)	1/7 (14%)	3/7 (43%)	nd	7/7 (100%)	nd	
	LSD Neethling Lumpyvax [1x104 TCID50] SC Route	7	7/7 (100%)	1 dpv (10.3day s)	0/7 (0%)	0/7 (0%)	0/7 (0%)	Nd	0/7 (0%)	0/7 (0%)	1/7 (14%)	4/7 (57%)	nd	5/7 (72%)	nd	
Holstein 6 months Male	LSD Neethling HerbivacLS [1x102.5 TCID50] SC Route	7	4/7 (57%)	1 dpv (3 days)	0/7 (0%)	3/7 (43%)	3/7 (43%)	nd	3/7 (43%)	4/7 (57%)	3/7 (43%)	5/7 (71%)	nd	6/7 (86%)	nd	Haegeman et al., 2021a
	LSD Neethling (O variant) MCI [1x103 TCID50] SC Route	7	4/7 (57%)	1 dpv (3.8 days)	3/7 (43%)	2/7 (29%)	3/7 (43%)	nd	2/7 (29%)	2/7 (29%)	4/7 (57%)	3/7 (43%)	nd	7/7 (100%)	nd	
	LSD KSGP Kenyavac [1x102.5 TCID50] SC Route	7	5/7 (71%)	1 dpv (6.8 days)	0/7 (0%)	0/7 (0%)	0/7 (0%)	nd	0/7 (0%)	0/7 (0%)	0/7 (0%)	2/7 (29%)	nd	5/7 (72%)	nd	
	LSD Neethling (LSD_Nt) [1x104 TCID ₅₀] SC Route: 2ml	15	7/15 (47%)	2 dpv (2 days)	0/15 (0%)	1/15 (7%)	1/15 (7%)	1/15 (7%)	1/15 (7%)	nd	7/15 (47%)	nd	nd	nd	nd	
Holstein-cross 4-6 months	LSD Neethling (LSD_Nt) [1x105 TCID ₅₀] SC Route: 2ml	30	13/30 (43%)	NI (4.3 days)	2/30 (7%)	2/30 (7%)	2/30 (7%)	2/30 (7%)	2/30 (7%)	nd	23/30 (73%)	nd	nd	nd	nd	Bamouh et al., 2021
	LSD KSGP O-240 [1x104 TCID50] SC Route: 2ml	12	5/12 (42%)	NI (5.6 days)	0/12 (0%)	0/12 (0%)	0/12 (0%)	0/12 (0%)	0/12 (0%)	nd	12/12 (100%)	nd	nd	nd	nd	
	LSD KSGP O-240 [1x105 TCID50] SC Route: 2ml	12	9/12 (75%)	NI (3.8 days)	1/12 (8%)	3/12 (25%)	3/12 (25%)	3/12 (25%)	3/12 (25%)	nd	12/12 (100%)	nd	nd	nd	nd	
Morocco (Zebu) 6-8 months	LSD Neethling OBP 1x104 TCID50 SC Route	15	1/15 (7%)	1 dpv (1 day only)	0/15 (0%)	0/15 (0%)	0/15 (0%)	0/15 (0%)	0/15 (0%)	nd	7/15 (47%)	nd	nd	nd	nd	Hamdi et al., 2020
Holstein- Friesen 9-10 months	LSD Neethling (Nt_hd) [1x107 TCID50] IV Route: 3ml & SC Route: 1ml	6	0/6 (0%)	N/A	2/6 (33%)	0/6 (0%)	0/6 (0%)	2/6 (33%)	0/6 (0%)	4/6 (67%)	4/6 (67%)	nd	5/6 (83%)	nd	6/6 (100%)	Moller et al., 2019
Holstein- Friesen 4-6 months	LSD Neethling HerbivacLS [1x102.5 TCID50] SC Route: 2ml	6	3/6 (50%)	5-6 dpv. (4-6 days)	5/6 (83%)	0/6 (0%)	5/6 (83%)	0/6 (0%)	nd	4/6 (67%)	5/6 (83%)	nd	5/6 (83%)	nd	nd	Wolff et al., 2020
	LSD Neethling (NVI, Ethiopia) [1x104.5 TCID50] SC Route	5	0/5 (0%)	N/A	0/5 (0%)	0/5 (0%)	0/5 (0%)	nd	nd	nd	nd	nd	nd	nd	0/5 (0%)	
Borana (Zebu) 12 -24 months	LSD Neethling (NVI, Ethiopia) [1x103.5 TCID50] SC Route	5	0/5 (0%)	N/A	0/5 (0%)	0/5 (0%)	0/5 (0%)	nd	nd	nd	nd	nd	nd	nd	0/5 (0%)	Gari et al., 2015
	LSD KSGP O-180 [1x104.5 TCID50 SC Route	5	0/5 (0%)	N/A	0/5 (0%)	0/5 (0%)	0/5 (0%)	nd	nd	nd	nd	nd	nd	nd	0/5 (0%)	
	LSD KSGP O-180 [1x103.5 TCID50 SC Route	5	0/5 (0%)	N/A	0/5 (0%)	0/5 (0%)	0/5 (0%)	nd	nd	nd	nd	nd	nd	nd	0/5 (0%)	
Dexter 11-16	LSD Neethling OBP [1x103.5 TCID50] SC Route: Vaccination 1	6	0/6 (0%)	N/A	0/6 (0%)	0/6 (0%)	0/6 (0%)	nd	nd	0/6 (0%)	0/6 (0%)	nd	nd	nd	nd	
months Male	LSD Neethling OBP [1x103.5 TCID50] SC Route: Repeat Vaccination 21 dpv	6	0/6 (0%)	N/A	0/6 (0%)	0/6 (0%)	0/6 (0%)	nd	nd	0/6 (0%)	4/6 (67%)	nd	nd	nd	nd	Osuagwuh et al., 2007
Holstein 6 months Male	LSD Lumpivax (KEVEVAPI, Kenya) [Dose: NI] SC Route: 2ml	7	7/7 (100%)	NI	7/7 (100%)	2/7 (29%)	7/7 (100%)	nd	3/3 (100%)	1/7 (14%)	nd	nd	1/7 (14%)	7/7 (100%)	nd	Haegeman et al., 2021b
Breed: NI 6-9 months Male	LSD Lumpi-ProVac Ind [1x103.5 TCID50] Route: NI	8	3/8 (37.5%)	NI	0/8 (0%)	0/8 (0%)	Viremia 5/8 (62.5%) 3dpv only	0/8 (0%)	0/8 (0%)	PCR 5/8 (62.5%) 3dpv only	7/8 (87.5%)	nd	nd	nd	nd	Kumar et al., 2022

Not all animals

naturally infected or vaccinated develop neutralizing antibodies against LSDV <u>or</u> they develop low levels of antibodies undetectable by current serological assays



Endemic since 1945 Annual outbreaks – Summer months


Diagnostic – Laboratory confirmation

- Molecular: Realtime PCR
- Serology: VNT
- Serology: IDVet ELISA
- Complete genome sequencing


Vaccination: Live attenuate Neethling vaccine:

- OBP vaccine Onderstepoort Biological Products, South Africa
- Herbivac Deltamune, South Africa
- Lumpyvax MSD Animal Health, South Africa
- Annual vaccination encourage

Education and information: 5 Languages







Antoinette van Schalkwyk Agricultural Research Council – Onderstepoort Veterinary Institute

vanschalkwyka1@arc.agric.za


Updates on bovine babesiosis -distribution and diagnosis-

Thillaiampalam Sivakumar




National Research Center for Protozoan Diseases Obihiro University of Agriculture and Veterinary Medicine, Japan

Bovine babesiosis and its economic importance




Babesia species capable of causing clinical bovine babesiosis


Babesia bovis



Babesia bigemina



Babesia divergens



Babesia naoakii - a new species that can cause clinical bovine babesiosis




Sivakumar et al. Parasites & Vectors (2022) 15:299 https://doi.org/10.1186/s13071-022-05374-9 Parasites & Vectors


BRIEF REPORT

Open Access

Phylogenetic analyses of the mitochondrial, plastid, and nuclear genes of *Babesia* sp. Mymensingh and its naming as *Babesia naoakii* n. sp.

Thillaiampalam Sivakumar¹, Bumduuren Tuvshintulga¹, Davaajav Otgonsuren¹, Enkhbaatar Batmagnai¹, Believe Ahedor¹, Hemal Kothalawala², Singarayar Caniciyas Vimalakumar³, Seekkuge Susil Priyantha Silva⁴, Junya Yamagishi⁵ and Naoaki Yokoyama^{1,6*}





Tick vectors of bovine Babesia species

B. bovis

Rhipicephalus microplus

R. annulatus

R. geigyi

B. bigemina

R. microplus

R. decoloratus

R. annulatus

R. geigyi


R. evertsi


B. divergens


Ixodes ricinus

B. naoakii Undetermined

Global distribution of bovine Babesia species










Diagnosis of bovine babesiosis

- 1. Risk factors
- 2. Clinical diagnosis
- 3. Parasitological diagnosis
- 4. Molecular diagnosis

Risk factors for clinical bovine babesiosis



1. Age Calves are resistant

2. Acquired immunity Acquired immunity protects cattle.


3. Management practices

Cattle managed extensively are more likely to develop immunity.


4. Endemic stability No or sporadic cases

5. Cattle breed *Bos indicus* is resistant, but not *Bos taurus*.

Clinical bovine babesiosis in endemic countries Scenario 1: endemic instability




Clinical bovine babesiosis in endemic countries Scenario 2: Introduction of naïve cattle



Clinical diagnosis

Intravascular hemolysis




High fever Anemia Jaundice







Bovine babesiosis caused by **B. bovis**





Parasitological diagnosis

Capillary blood — Thin smears — Staining — Microscopy

Characteristics	B. bovis	B. divergens	B. bigemina	B. naoakii	
Size (µm)	Small 1–1.5 × 0.5–1.0	Small 1–1.5 × 0.5–1.0	Large 3–3.5 × 1–1.5	Large 2.3–3 × 1.6–2.2	
Location in RBC	Central	Rim Entire RBC		Entire RBC	
Angle between paired merozoites	Obtuse	Obtuse	Acute	Obtuse	
Parasitemia in acute infection	Low (<1%)	High	High	High	

Molecular diagnosis





Specific and sensitive

Early diagnosis is important.

A survey of clinical bovine babesiosis in Sri Lanka

No.	Breed	Age	RBC indices		<i>Babesia</i> spp.	Treatment	Prognosis	
			HGB	НСТ	RBC			
1	Jersey	4	ND	ND	ND	Bbo + Bbi	Diminazene	Recovered
2	Friesian	3	8.4	22.6	5.65	Bbi	Diminazene	Recovered
3	Jersey	4	9.6	27.6	5.94	Bbi	Diminazene	Recovered
4	Friesian	4	6.8	19.6	3.94	Bna	Diminazene	Recovered
5	Jersey	5	2.8	7.9	1.38	Bbo + Bbi	Diminazene	Died
6	Jersey	4	8.7	24	5.59	Bbo + Bbi	Diminazene	Recovered
7	Jersey	4	9.4	25.7	5.51	Bbo + Bbi	Diminazene	Recovered
8	Jersey	5	ND	ND	ND	Bbo + Bbi + Bna	Diminazene	Recovered
9	Jersey	4	6.8	21.9	3.88	Bbo	Diminazene	Recovered
10	Jersey	5	6.7	21.5	3.5	Bbi	Diminazene	Recovered
11	Jersey	6	2.83	10.6	2.22	Bbi	Diminazene	Died
12	Jersey	3	4.8	13.3	3.03	Bbo + Bbi	Diminazene	Died
13	Jersey	6	ND	ND	ND	Bbo + Bbi	Diminazene	Recovered

ND, Not done; Bbo, B. bovis; Bbi, B. bigemina, Bna, B. naoakii

(HGB: g/dl, HCT: %, RBC: × 10⁶/µl)

Cattle with severe anemia died.

Treatment and prevention

Treatment

Therapeutic dose and route of administration

Drug	Dose	Route
Diminazene aceturate	3.5 mg/kg	Intramuscular
Imidocarb	1.2 mg/kg	Subcutaneous

Prevention

Tick control

Vaccination with live-attenuated B. bovis and B. bigemina strains

Summary

1. Causative Babesia B. bovis, B. bigemina, B. naoakii, and B. divergens

> **2. Lifecycle and transmission** Transmitted to cattle by specific tick vectors

> > **3. Pathogenesis and clinical signs** Hemolytic anemia, cerebral babesiosis, and immunodisease



4. Risk factors

Age, acquired immunity, grazing management, endemic status, and breed

5. Diagnosis

Clinical, parasitological, and molecular diagnosis

6. Treatment

Chemotherapy and supportive therapy

7. Prevention

Tick control, vaccination, and chemoprophylaxis

Contact us



Dr. Thillaiampalam Sivakumar sivavets@gmail.com



WOAH Reference Laboratory for Bovine Babesiosis



Dr. Naoaki Yokoyama yokoyama@obihiro.ac.jp

Visit our website for further details

World Organisation

for Animal Health

https://www.obihiro.ac.jp/facility/protozoa/en/woah-reference-centres

Distribution, surveillance and diagnosis of JEV in animals


Dong-Kun Yang/ WOAH expert for JE

2024. 9. 19



World Organisation for Animal Health Founded as OIE

Distribution of JE in human in Asia and Pacific region




- □ Map of countries in Asia and Pacific region where JEV has been identified
- JEV has the biggest population in endemic countries among vector borne diseases

Why is JE important in animals ?

- Since the first case of JEV infection was reported in 1871, JEV infections have been reported in human and animals.
- Public health impact: JE is a significant public health concern, especially in Asia and the Western Pacific regions, where it causes thousands of cases and deaths annually.
- Neurological damage: JE can lead to severe neurological damage, including encephalitis, seizures, and long-term cognitive and motor impairments. Approximately 20-30% of those who develop encephalitis die, and 30-50% of survivors suffer from permanent neurological sequelae.
- □ **Lack of specific treatment**: There is no specific antiviral treatment for JE.
- Economic burden: The disease imposes a significant economic burden on affected families and healthcare systems due to the high costs of medical care and long-term rehabilitation for survivors.
- Preventable disease: JE is preventable through effective vaccination programs and mosquito control measures.

Characteristics of *Cx. tritaeniorhynchus*, *Cx. orientalis* transmitting JEV 3 or 5



Culex tritaeniorhynchus


Culex orientalis

PCAS/FEHD/HKSARO

The *Cx. tritaeniorhynchus and Cx. orientalis* are associated with transmission of JEV genotype 3 and 5 respectively.


Habitat preference: *Culex orientalis* is commonly found in rice paddies, marshes, and other stagnant water bodies. These environments provide ideal breeding grounds for the mosquito, facilitating its role as a vector for JE. **Feeding behavior**: This mosquito species is primarily zoophilic, meaning it prefers to feed on animals rather than humans. However, it can still bite humans, especially when animal hosts are scarce.

JE cases in human and swine in South Korea since 2002




There has been no JEV infection in swine since 2008. But. 17 JE cases occurred in human in 2023. JEV genotype 5 has been identified in human since 2010. JE vaccine belonging to JEV 3 has been used for Korean and animals.

Distribution of JEV genotype in Asia in 2022



From 2009, the hidden genotype 5 suddenly emerged from the Tibetan region of China and from South Korea in East Asia. Similarly, **in 2022** the long silent genotype 4 of JEV emerged in Australia.

JEV genotype shift is occurring in Korea



The detecting and monitoring the JEV carried by mosquitoes in the natural environment are effective method that can help to predict whether JE genotype strains have the potential to cause human infection or not.

JEV infection was identified in a seal residing in a zoo



A seal resided in a wild zoo located in Southern region of Korea was commissioned to APQA in 2017. The seal died of heartworm and JEV infection.

The JEV was classified into JEV genotype 1 based on the nucleotide sequence analysis.

Why do we conduct serological survey for JEV?

- Early detection of antigen: Serological tests help in the early detection of JEV in animal populations, which is crucial for monitoring and controlling potential outbreaks. This early detection allows for timely interventions to prevent the spread of the virus to humans and other animals.
- **Understanding transmission dynamics**: This information is vital for identifying key reservoir hosts and vectors, such as pigs and mosquitoes, which play significant roles in the virus's life cycle.
- Evaluating vaccination programs: Serological testing is essential for assessing the effectiveness of vaccination programs in animals. By measuring antibody levels, researchers can determine the immunstatus of animal populations and make informed decisions about the need for booster vaccinations or other preventive measures.

Considerations before serological test

[Pig & Horse]

- 1. Vaccination (Live-attenuated vaccine)
 - Vaccination policy to sow population in Korea
 - Vaccination to racehorse population
- 2. Maternal antibodies
- 3. Another flavivirus infection? [Other animals]



[Solution]

1. Vaccination or maternal antibodies : Sampling paired sera

2. Other *flavivirus* infection : Cross neutralization test

- e.g. JEV \iff WNV(exotic) : difference above 4 fold dilution


How to conduct HI test



The commercial HI kit for JEV




Goose red blood cells packed 100%




The commercial HI kit for the detection of JEV antibodies is available for animals.

Example of PRNT to detect JEV antibodies




- The principle of plaque assay is to differentiate accumulated dead cells by virus infection from surrounding surviving cells.
 - PRNT ₉₀ means 90% of JEVs were inhibited by antibody within serum.
- There are some limitations of PRNT in testing large numbers of sera.

Correlation between ELISA and HI test




• These results suggest that I-ELISA is useful for sero-surveillance of JEV in swine.

Sero-surveillance of JEV in pigs since 2004




- Sera obtained from 5,000 to 8,000 pigs each year have been checked by HI or ELISA test since 2004.
- HI and ELISA tests have been used to measure JEV antibodies in pig sera since 2017.
- If all sows on a pig farm are negative for JEV, vaccination is recommended.

Sero-surveillance of JEV in wild birds captured in South Korea




- Blood samples were collected from 1,316 wild birds including migratory birds in 16 sites of 6 provinces.
- Of the 1,316 serum samples tested, 1,141 sera (86.7%) were positive for JEV.
- Migrating birds are believed to be one of the factors responsible for transmitting the JEV.
- When the chicken is sero-positive against JEV, it means the widespread presence of JEV.

Sero-surveillance of JEV in wild boars in South Korea



- The results showed that 66.0% (190/288) of wild boars in Korea had neutralizing antibodies against JEV.
- Wild boars are amplifying hosts of the JEV and are believed to be one of transmitters.

Sero-surveillance of JEV in horse sera



- Of the 1,331 horse sera collected in 2023, 85.5% were positive for JEV.
- As a result of analyzing regional distribution, the number of horses in Daejeon was the lowest at 66.7%.
- The JEV antibodies in horse are an immune response following vaccination and JEV vaccine is recommended for antibody-negative horses.

Overview of diagnosis of JEV antigen in animals


	Purpose							
Method	Population freedom from infection	Individual animal freedom from infection prior to movement	Contribute to eradication policies	Confirmation of clinical cases	Prevalence of infection – surveillance	Immune status in individual animals or populations post- vaccination		
Detection of the agent ¹								
Virus isolation	-	-	-	+++	-	-		
Antigen detection	+	+	+	+	+	-		
Real-time RT-PCR	++	++	++	+++	++	-		

• Diagnostic test methods including virus isolation, real time RT-PCR, mouse inoculation have been used to detect JEV antigens.


Diagnosis of JE in pigs and horses

- Most JE infection in sows manifests as a reproductive disease to reach 50–70% abortions in sows, subclinical in horses.
- □ Stillbirths or mummified fetuses; usually at term
- Live born piglets most often demonstrate neurologic signs of tremors and convulsions and may die soon after birth.
- □ Mild febrile disease or subclinical disease in non-pregnant females
- □ Natural infection results in long lasting immunity
- \Box Mortality rate is near zero in adult swine
- □ Identification of JEV on brain or spinal cord in horse
 - Under 70-day old fetus: JEV antigen has to be identified with VI, or RT-PCR.
 - Over 70-day old fetus: JEV antibody on thoracic fluid should be checked.


Host response to JE infection



+/+: Positive results in both virus isolation and real-time RT-PCR. Because of short period of viremia, the timing of virus detection must be considered.




Multiplex RT-PCR and real time RT-PCR kit to detect JEV



- Conventional RT-PCR kits for the detection of JEV in brain, fetal fluid and sera have been commercialized.
- Real time RT-PCR kit is also available to detect JEV in samples.


Example of application of real time RT-PCR kit to JEV genotypes



1.18 TCID₅₀/mL


6.48 TCID₅₀/mL

20.77 TCID₅₀/mL




- The real time RT-PCR kit detected three genotypes of JEV and showed the lowest detection limit to JEV genotype 1 of 1.18 TCID₅₀/ml.

Proliferation ability of JEVs in 3 types of cells



- JEV has different proliferative abilities depending on the cells.
- BHK-21 and C6/36 cells are suitable for isolating JEV.
- C6/36 cells should be culture at 28 degrees.

Mouse inoculation test to detect JEV



- **The 3-5 day old nursing mice** inoculated with JEV showed paralysis, signs of nerve system and died within 7 days post inoculation.
- **Four-week old mice** inoculated with JEV via intracranial route died of neurologic disease. The most susceptible five mouse species to the JEV are C3J/He, DBA/2, C57BL/6, Balb/c, ICR.

How to control JE in animals


- Vaccination: Implementing vaccination programs for animals, especially pigs, can significantly reduce the spread of JEV. Vaccines help build immunity in animal populations, preventing the virus from amplifying and spreading.
- **Mosquito control**: Reducing mosquito populations through environmental management, such as eliminating standing water where mosquitoes breed, and using insecticides can help control the primary vectors of JEV.
- Active surveillance: Regular surveillance and monitoring of animal populations for signs of JEV can help in early detection and prompt response to outbreaks. This includes serological testing to identify infected animals.
- **Public awareness and education**: Educating farmers and animal handlers about the importance of mosquito control, vaccination, and early detection measures can enhance the effectiveness of control programs. Awareness campaigns can also promote the adoption of best practices to prevent the spread of JEV.

JEV vaccination and vector control

- Vaccination is the most effective preventive method for animals.
- Minimizing exposure of animals to mosquitoes using nets is possible.


Туре	Virus strain	Culture method	For use in	Genotype	
Inactivated JE	Nakayama	Chicken embryos Horse/pigs		3	
Inactivated JE	Beijing	- Horse/pigs		3	
Live JE	AT	Hamster kidney cell Pigs		3	
Live JE	Μ	Hmlu-1	Pigs	3	
Live JE	Anyang300	Duck primary cell	Pigs	3	
Live JE	SA-14-14-2	BHK-21 cells	human and Pigs	3	
Live JE	M-17	Porcine kidney cell	Pigs	3	

• Vectors can be controlled by using insecticides in rice fields, growing larvivorous fish and mosquitofish.





Example of JEV vaccine application on pig farms



- In total, 3,790 sows were inoculated with JEV vaccine in three provinces in 1975.
- The stillbirth rate in sows inoculated with JEV vaccine was reduced rapidly.
- But sows that were not treated with JEV vaccine showed high still birth rates (92.5 to 96.7%).

Summary

- **Continuous cooperation and efforts** are needed to improve human and animal health.
- Strengthen the monitoring of JEV gene changes: it is essential to enhance methods for detecting and monitoring JEV genotypes in the natural environment. In Europe and Africa, JEV infections were reported.
- Enhanced surveillance for early detection: as mosquito activity is expanding due to climate change, active surveillance into JEV is required in Asian countries.
- Vaccination: continuous vaccination of pigs and horses is recommended to prevent JEV infection in animals.
- **Development of new JE vaccine**: the JEV 3 vaccine has the protection rate against JEV 1 ranging from 92% to 97%.

ΤΕ Γ Α Μ Ο

IZS


West Nile Fever

WOAH Regional Workshop on Vector Borne diseases in Asia and the Pacific

Federica Monaco f.monaco@izs.it Istituto Zooprofilattico Sperimentale dell'Abruzzo e del Molise "G. Caporale" WOAH Reference laboratory for WNF

Tokyo, 19th September 2024

West Nile virus



West Nile virus (WNV) is a mosquito-borne virus belonging to the genus *Flavivirus* in the *Flavivirida*e family capable of infecting a wide range of species

Serologically, West Nile virus is a member of the Japanese encephalitis serocomplex

RAMO

ZOOPROFILATTICO

SPERIMENTALE DELL'ABRUZZO

E DEL MOLISE


"G. CAPORALE"

F

ISTITUTO

2

West Nile virus



T E R A M O / ISTITUTO ZOOPROFILATTICO

SPERIMENTALE DELL'ABRUZZO E DEL MOLISE "G. CAPORALE"

ERAMO




WNV is maintained in nature by enzootic cycle between **adult ornithophilic mosquitoes** in mainly belonging to the **Culex**, genera and several bird species

WNV is predominantly vectored worldwide by members of the Culex pipiens complex

Horses and humans are considered dead end hosts of the virus and do not contribute to the transmission cycle

West Nile virus



Global distribution of Cx. pipiens complex mosquitoes. Geographic range for Cx. p. pipiens includes both forms (pipiens and molestus). Cx. australicus and Cx. globocoxitus are restricted to Australia. (Ciota and Kramer 2013)

Cx quinquefasciatus

ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELL'ABRUZZO E DEL MOLISE "G. CAPORALE"

The incubation period is 2-14 days


80% of human infections have no symptoms

About 20% of WNV infections in humans may cause West Nile fever (WNF),

Less than **1%** may cause West Nile neuroinvasive disease (WNND) that affects the nervous system.

1 WNND ===== 150 infections

Symptoms in human



ERAMO

The **incubation period** is 3–15 days

The infection usually is asymptomatic (>70%) or with mild symptoms like fever, weakness, myalgia (20%):

- 1-10% of infected horses has the neuroinvasive form
- virus in the CNS (spinal cord, hindbrain, midbrain)


The fatality rate in horses can reach 57-60%

- In USA (2000) was 38.3%
- In Italy was 42% (1998), 15.6% (2008) Infection
 24.3% (2009)


Viremia precedes the clinical manifestations of disease Rarely, horses are symptomatic AND viremic

Symptoms in horses





Bunning et al., 2002




Birds



Over **300 species** of birds have been identified as viable WNV hosts

There is significant variability in viremia levels and disease


Clinical signs following WNV infection is uncommon and related to bird **species** (birds of prey) and **viral strain**




8

ERAMO

ISTITUTO ZOOPROFILATTICO **SPERIMENTALE** DELL'ABRUZZO E DEL MOLISE "G. CAPORALE"





WNV L2

Mencattelli et al., 2023

IZS.IT

Transmission - SoHO

The virus can also spread between humans through blood transfusion and organ transplant. Other ways in which the virus can spread are from mother to child during pregnancy and breastfeeding and through laboratory exposure





IZ

ISTITUTO

ERAMO

ZOOPROFILATTICO SPERIMENTALE

DELL'ABRUZZO E DEL MOLISE

"G. CAPORALE"


ERAMO




Early detection of WNV circulation for rapid risk assessment and adoption of appropriate preventive measures in **public health**.

Surveillance of WNV circulation requires a multidisciplinary effort

complexity of the epidemiological cycle





Entomological and veterinary surveillance are keys:

- to assess the associated human health risk
- to trigger a more timely and effective control of the disease in humans

ERAMO

WNV surveillance: the Italian model

High transmission risk area

Territories (Provinces NUT-3) where WNV is circulating or has circulated in at least one of the 5 years before as well as the surrounding areas

Low transmission risk area

Territories (Provinces NUT-3) where WNV has never been/rarely reported, which have eco-climatic condition favorable to viral circulation

Minimum transmission risk area

Territories (Provinces NUT-3) where WNV has never been reported and where ecoclimatic conditions are not suitable to WNV circulation



✓ Surveillance of resident birds of target species (Magpie, Carrion

Crow and Eurasian jay) in High and Low risk areas
 ✓ alternatively in Low risk areas surveillance can be conducted on rural or open air poultry rearing units.

Veterinary surveillance is focused on the following components:

- Entomological surveillance. High and Low risk areas (1 trap/20X20 km)
- ✓ Horses clinical surveillance. (whole country)
- ✓ Wild bird mortality surveillance (whole country)

To guarantee harmonization and representativeness of the data collected within active surveillance each province (NUT-3) is divided in units of 1200–1600 km2 and activities referred to each unit.








ISTITUTO


ERAMO

ZOOPROFILATTICO SPERIMENTALE

DELL'ABRUZZO

E DEL MOLISE "G. CAPORALE"









The recent and massive availability of **Earth Observation (EO)** data and the continuous development of innovative **Artificial Intelligence (AI) methods** can be of great help

- to automatically identify patterns in big datasets
- to make highly accurate predictions
- to define intervention priorities within national diseases surveillance plans

West Nile Virus Spread




AIDEO: AI and EO as Innovative Methods for Monitoring



Predicting WNV Circulation in Italy Using Earth Observation Data and Extreme Gradient Boosting Model

Luca Candeloro^{1,+}, Carla Ippoliti¹⁰, Federica Iapaolo¹, Federica Monaco¹, Daniela Morelli¹, Roberto Cuccu², Pietro Fronte², Simone Calderara³, Stefano Vincenzi³, Angelo Porrello³, Nicola D'Alterio¹, Paolo Calistri¹ and Annamaria Conte¹

- ¹ Istituto Zooprofilattico Sperimentale dell'Abruzzo e del Molise 'G.Caporale', 64100 Teramo, Italy; cappoliti@iszait (C.1); faipaolo@iszait (EL); famonaco@iszait (F.M.); d. moreli@iszait (D.M.); n.dalterio@iszait (N.D.); p.calistri@iszait (F.C.); a conte@iszait (A.C.)
- ² Progressive Systems SrI, Frascati, 00044 Rome, Italy; roberto.cuccu@progressivesystems.it (R.C.); pietro.fronte@progressivesystems.it (P.F.)
- AlmageLab, Engineering Department "Enzo Ferrari", University of Modena and Reggio Emilia, 41121 Modena, Italy: simone-calderara@unimore.it (S.C.); stefano.vincenzi@unimore.it (S.V.); angelo.porrello@unimore.it (A.P.)




www.aideo.eu https://eo4society.esa.int/projects/aideo/

🖵 Previsioni Caricamento previsione dapest dal 28/08/2024 al 12/09/2024 AUSTRIA OLDOVA V La previsione utilizza una versione aggiornata (che include i dati WND HUNGARY luj-Napoca • 2020) del modello descritto gui SLOVENIA ROMANIA R A M E ljana 🔹 📚 Layer Braso CROATIA ISTITUTO Banja Luka ÷. Focolai • Bel ZOOPROFILATT BOSNIA AND Bucharest Confermato Cratova **SPERIMENTALE** Sospetto Sarajevo SERBIA Estinto DELL'ABRUZZO E DEL MOLISE Regioni Sofia BULGARIA Podeorica "G. CAPORALE" Previsioni 0,0 - 0,1 NORTH 0,1 - 0,2 Tirana . Istanbul 0,1 - 0,3 0,3 - 0,4 ALBANI 0,4 - 0,5 0,5 - 0,6 na de 👘 0,6 - 0,7 0,7 - 0,8 GREECE 0,8 - 0,9 0,9 - 1,0 MALTA TUNISIA

https://mapserver.izs.it/gis_wn_predictions/#

Mosquitoes dashboard



https://www.arcgis.com/apps/dashboards/282dbe6c42264e9aba37bef5524367b1

F

ISTITUTO

E DEL MOLISE

ERAMO

Т



https://westnile.izs.it/j6_wnd/home_en

IZS

Raccolta Integrated surveillance of West Nile and Usutu virus

These annual reports summarize the results of West Nile virus and the Usutu virus surveillance activities in Italy



5 2019



https://storymaps.arcgis.com/collections /b50666024702441dac792d0cb3aee32c

Reports

References

ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELL'ABRUZZO E DEL MOLISE "G. CAPORALE"

ΤΕ Γ Α Μ Ο

- ✓ Bunning et al. Experimental Infection of Horses with West Nile virus. Emerg Infect Dis. 2002 Apr;8(4):380-6. doi: 10.3201/eid0804.010239.
- ✓ Candeloro et al. Predicting WNV circulation in Italy using Earth Observation data and extreme gradient boosting model. Remote Sensing (2020) 12 (18), 3064.
- ✓ Ciota and Kramer.Vector-virus interactions and transmission dynamics of West Nile virus. Viruses. 2013 Dec 9;5(12):3021-47. doi: 10.3390/v5123021
- ✓ Ciota. West Nile virus and its vectors. Current Opinion in Insect Science, Volume 22, 2017, Pages 28-36, ISSN 2214-5745. <u>https://doi.org/10.1016/j.cois.2017.05.002</u>.
- ✓ De Ascentis et al. 2022. Species of mosquitoes present in Abruzzo and Molise and their possible role as vector of Usutu and West Nile viruses. Vet Ital. doi: 10.12834/VetIt.3046.20276.1
- ✓ Diagne et al. Novel Amplicon-Based Sequencing Approach to West Nile Virus. Viruses. 2023 May 27;15(6):1261. doi: 10.3390/v15061261.
- ✓ European Centre for Disease Prevention and Control. Vector control practices and strategies against West Nile virus. Stockholm: ECDC; 2020.
- ✓ Komar et al. Experimental infection of North American birds with the New York 1999 strain of West Nile virus. Emerg. Infect. Dis., 9 (2003), pp.311-322.
- ✓ Mencattelli et al. Spatial and temporal dynamics of West Nile virus between Africa and Europe. Nat Commun. 2023 Oct 13;14(1):6440. doi: 10.1038/s41467-023-42185-7.
- \checkmark CDC. Species of dead birds in which West Nile virus has been detected, United States, 1999–2016.
- ✓ https://www.cdc.gov/west-nile-virus/media/files/Bird_species_West_Nile_virus_U.S..pdf



WOAH Regional Workshop on Vector Borne diseases in Asia and the Pacific 19-20 September 2024



Leishmaniasis

Fabrizio Vitale

Direttore Area Biologia Molecolare Responsabile Centro di Referenza Nazionale Leishmaniosi (CRENAL) WOAH Leishmania Reference Lab. Expert Responsabile Laboratorio Entomologia e Controllo Vettori Ambientale (EVA) Istituto Zooprofilattico Sperimentale della Sicilia via Gino Marinuzzi 3 - 90129 – Palermo fabrizio.vitale@izssicilia.it +390916565368 +393357895724

CHENGL - COULDO OF the

WOAH Reference Laboratory

World Organisation for Animal Health

for Leishmaniasis

Reference Centre




WOAH Regional Workshop on Vector Borne diseases in Asia and the Pacific

What are we talking about?

The leishmaniases are a group of diseases caused by the protozoa parasite Leishmania.

The diseases mainly affects poor people in Africa, Asia and Latin America, and is associated with malnutrition, population displacement, poor housing, weak immune system and lack of resources.

Out of 200 countries and territories reporting to WHO, 99 countries and territories are endemic for leishmaniasis in 2022. This includes 71 countries that are endemic for both VL and CL, 9 countries that are endemic for VL only and 19 countries that are endemic for CL only.



https://www.researchgate.net/publication/228638177_Trypanosomatids_Odd_Organisms_Devastating_Diseases#:~:text=Trypanosomatids%3A%20Odd%20Organisms,4(1)

But also dogs, cats, humans and many others...







Why dogs, cats and many others?

Of the various Leishmania species most are zoonotic, so a zoonotic disease (zoonosis) is one that "jumps" from an animal to a human. These animals are known as "reservoir hosts" and play an important role in the transmission of Leishmania infection and are able to keep the pathogen that causes the disease, alive, over time, in an ecosystem.

MEMENTO

An excellent reservois should:

- Offers optimal conditions for the reproduction and <u>perpetuation</u> of the microorganism.
- Being keep in touch with humans by sandflies;
- Be receptive to the pathogen;
- Be available for carriers;
- Offer the main food resource for sandflies and share the same habitat.

It is evident that the dog is an example of a good reservoir for Leishmania

But...

Is the dog more likely to be a "victim" rather than a reservois?



Thus... Why do the programs of mass killing of dogs (conducted in various parts of the w on several occasions, in Brazil) fail to control human visceral leishmaniasi





WOAH Regional Workshop on Vector Borne diseases in Asia and the Pacific

Why dogs, cats and many others?

The fatal nature of canine disease suggests that this species is a recent host in evolutionary terms (Campino, 2002).





Table 6. Wild anim employed for detec	1 1 /	antum from Europe, Asia and Africa. Orgar	ns or tissues whe	re the parasite was detected are	e indicated, as well as the techniques		
Host Order Carn	Microorganisms 2021 , 9, 1101						
Canis aureus (gole							
Canis lupus (gr				Table 6. Cont.			
Felis silvestris (Host	Microorganisms 2021, 9, 1101					31 of
_	Order Chiroptera						
Genetta genetta (con Herpestes ichn	Pipistrellus pipistrellus (comm urban bat)				Table 6. Cont.		
(Egyptian mor	Order Diprotodontia						
Lutra lutra (Eura Lynx pardinus (Ib	Macropus rufogriseus (Bennett's wallaby)	Host Order Rodentia	Prevalence	Organs/Tissue Analysed	Methods for Detection	Country	References
Martes foina (been Martes martes (E	Order Eulipotyphla	Apodemus sylvaticus (wood mouse)	20-50%	blood, BM, liver, skin, spleen	PCR (ITS1) + sequencing, PCR-ELISA (kDNA), qPCR (kDNA) + RFLP + sequencing, PCR (ITS2) + RFLP, smear, culture	Spain	[128,129,159]
pine mart	Atelerix algirus (Algerian hedg	Crocidura russula (white-toothed shrew)	13.3%	blood and/or spleen	qPCR (kDNA)	Spain	[160]
Meles meles (Europ Mustela lutreola (Eur	Erinaceus europaeus (Europe hedgehog)		22-50%	blood, BM, liver, skin, spleen	qPCR (kDNA) + sequencing, PCR (ITS1) + sequencing, PCR-ELISA (kDNA), nPCR (SSU and ITS1) + sequencing, smear	Morocco, Portugal and Spain	[162,163]
Austela putorius (Eur Mustela vison (Ame	Order Lagomorpha	Mus spretus (Algerian mouse)	4.3-42.9%	blood, liver, skin, spleen and serum	qPCR (kDNA), ELISA	Spain	[137,160]
Panthera tigris Sciurus vulgaris (r	Lepus europaeus (European h	(short-tailed handicoot rat)	39%	liver, skin, spleen,	nPCR (kDNA), smear	Iran	[162]
Ursus arctos (brc	Lepus granatensis (Iberian ha Oryctolagus cuniculus	Rattus norvegicus (brown rat)	5.9-100%	hair, liver, skin, spleen	nPCR (SSU), nPCR (ITS1) + sequencing, qPCR (kDNA), PCR (kDNA), PCR (kDNA) + RFLP, PCR (ITS2) + RFLP, smear	Greece, Morocco,	[129,131,162
Vulpes vulpes ((European rabbit)	Rattus rattus (black rat)	7.5–33.3%	blood, BM, liver, skin, spleen	PCR (kDNA) + sequencing, PCR (ITS1) + sequencing, PCR-ELISA (kDNA), nPCR (SSU), nPCR (ITS1) + sequencing		A COMPANY
	Pongo pygmaeus (north we Bornean orangutan)	bin. bone marrow, cyrb. cytoenom	al transcriber space	uorescence antibody assay; GAI	smear, culture, inoculation to hamster, isoenzymes DPH: glyceraldehyde phosphate dehydrogenase; IC: immunochromato; lymph node; nPCR: nested PCR; qPCR: quantitative PCR; RFLP: restriction		

Review A Systematic Review (1990–2021) of Wild Animals Infected with Zoonotic Leishmania

World Organisation for Animal Health

Founded in 1924



WOAH Regional Workshop on Vector Borne diseases in Asia and the Pacific

Vectors (sandflies)

Wild environments

Land turtle nests

Drainage ditches

Termite mounds

Rodent burrows

Shaft recesses

Roots of large trees

Soil at the base of trees

Under and between boulders

Soil under overhanging boulders

Forest Floor

Ant nests

Bird nests

Caves

That's all?

Over 1000 species of sandflies are known but less than 50 are credited with the transmission of Leishmanias.


The vector typically:

She is female

Performs the blood meal in the evening/night hours It has a seasonality (warm-temperate temperatures) It remains a few hundred meters from the place of

birth

The larvae of sandflies are "terrestrial"



X

Peri-domestic environments Animal dens Animal shelters Chicken coops Soil debris and cracks Rotting manure heaps Earth at the base of old walls Under the stones


<u>Domestic</u>

Basements and cellars Abandoned houses Cracks in floors and walls





Surveillance strategy: focus on Leishmaniasis






Assess health of a population


identify the etiology or cause of disease.

The interaction between living beings, which share the same environment, should be considered as a single dynamic system, in which the health of each component is inevitably interconnected and dependent on the others.

1.




Killick-Kendrick R. Phlebotomine vectors of the leishmaniases: a review. Med Vet Entomol. 1990;4(1):1-24



Distribution range of sandflies according to





million

Canine leishmaniasis is present in >70 countries

Many more in South America

Infected dogs in Italy, Spain, France and Portugal are around 2.5

determine the extent of disease.

The surveillance activity is focused in Europe on the main synanthropic reservoir of the disease: the dog and develops at a regional level on the basis of some considerations:

- Canine reservoir on the rise in non-endemic areas
 - Rapidly spreading vector phlebotomine habitat
 - Interregional Dog Handling
 - Improved information flow Human and animal health



- Table 2. The table below shows the clinical form of leishn



WOAH Regional Workshop on Vector Borne diseases in Asia and the Pacific

Determine causes of any health problems

1.

study the progression of the disease.




Where are we?

Its strategic location at the centre of the Mediterranean has made the island a crossroads of history, a pawn of conquest and empire, and a melting pot for ethnic groups, vegetal inflorescence and...arthropods!

Why do we care so much about climate changes?

The arthropod vectors of diseases are ETEROTHERMIC organisms (without temperature regulation system) and therefore they depend on the environmental temperature

Climatic suitability of vector species and distribution of associated pathogens. Hatched areas indicate the observed distribution of the five Leishmania species, red indicates areas with suitable climatic conditions based on the binary modelling results equal training using sensitivity and specificity threshold projected for at least one of the associated vector species (with confirmed or strongly suspected vectorfor the competence respective Leishmania species).



Leishmaniasis in Eurasia and Africa: geographical distribution Issue: 5, DOI: (10.1098/rsos.190334)





Determine causes of any health problems

evaluate preventive and therapeutic measures for a disease

Preventing Leishmaniasis

KEY POINTS

- There are no vaccines or drugs to prevent leishmaniasis infection.
- The best way people can prevent infection is to protect themselves against sand fly bites.

Joint Effort – Applied Surveillance Purpose:

- ✓ Track sand fly populations
- ✓ Evaluate Control effectiveness
- ✓ ID sand fly & disease "hot spots"
- ✓ Determine Leishmania infection rates
- ✓ Which trap designs are most effective

Prevention

Leishmaniasis is mainly prevented by suppressing and killing sandfly vectors which transmit the disease (vector control measures). Vector control measures are critical to reducing disease incidence in the absence of an effective vaccine.

CDĆ

1.

The primary strategies of vector control are indoor residual spraying (IRS) and long-lasting insecticide-treated nets (LLINs) with pyrethroid insecticides. IRS involves spraying the walls and other surfaces of houses and buildings, LLINs offer protection to individuals.

Table 5 Current treatment protocols for canine leishmaniosis [27]

Drugs	Dosages	Main side effects	References
Meglumine antimoniate*	75-100 mg/kg once a day or 40-75 mg/kg twice a day for 4 weeks, S.C.**	Potential nephrotoxicity Cutaneous abscesses/cellulitis	[52,55,57,81-83]
Miltefosine*	2 mg/kg/once a day for 28 days P.O.	Vomiting Diarrhea	[83-85]
Allopurinol	10 mg/kg twice a day for at least 6-12 months P.O.	Xanthine urolithiasis	[51,59,86-89]

*Registered for veterinary use in most European countries; both drugs are commonly recommended in combination with allopurinol.

P.O.: per os; S.C.: subcutaneous

**Treatment prolongation by 2-3 weeks may be considered if patient improvement is insufficient.

Table 6 Treatment of canine leishmaniosis - recommended monitoring of clinicopathological parameters and serology including frequency of follow up [27]

Parameters	Frequency			
Clinical history and complete physical examination	After the first month of treatment and then every 3-4 months during the first year. Later on, if the dog is fully recovered clinically with treatment, a recheck			
Routine laboratory tests:	would be recommended every 6 months or once a year.			

Complete CBC, biochemical profile, serum electrophoresis (optional) and complete urinalysis including UPC in proteinuric dogs.

Serology*	Not before 6 months after initial treatment and every 6 months or one year thereafter.	te a
Real time PCR	Can optionally be causefulness of this as undetermined.	
with clinical improvement within 6 months to	body levels (more than a two-fold dilutions differ ear of treatment. Other dogs might not have a do ore than two-fold elevation between monitoring s f treatment [27].	
	Solano-G http://w	
	LeishVet	

of canin



Implement & evaluate solutions

develop public health policy.



Sandfly biting activity is strongly seasonal, restricted to summer months in most areas (e.g. Southern Europe, below 800m above sea level)

Future & climate change

Prolonged activity periods and shorter diapause periods (overwintering)

Extend northwards and into higher altitudes

At present, no good prediction models available



@PEANUTSSPECIALS



Leishmaniases remain widespread and under-reported. Measures for leishmaniases prevention and control, access to valid diagnostic methods and guidelines, and access to effective treatments vary considerably between countries. This variation and the lack of resources in some countries or regions, could have important disease implications including increased incidence; unnoticed spread of Leishmania spp. into new areas; increased treatment failure and development of resistance to treatments.

1.

TECHNICAL REPORT Surveillance, prevention and control of leishmaniases, EFSA, ECDC

What needs

- Public health surveillance at the International level (mandatory notification system in all countries?)
- Educate people on interventions against sandflies
 - Insect repellents Insecticides
 - Use of insecticide impregnated nets and bed nets
 - Dog: topical applications and impregnated collars
- Further research on

٠

.

•

- Alternative modes of transmission
- Effective vaccine for human leishmaniasis
 - · immunisation strategy for human populations
- Effective vaccine for canine leishmaniasis
 - to control the infections in reservoir population (dogs, cats, hares
- Better predictive modelli





WOAH Regional Workshop on Vector Borne diseases in Asia and the Pacific

Leishmaniasis: An example of how essential the concept of One Healing



Thank you ...

- Medical doctors to recognize and treat human clinical forms (CL / VL)
- Veterinarians to recognize and treat animal clinical forms
- Biologists to optimize research laboratories
- Entomologists to monitor vectors
- Wild experts to identify non-anthropized reservoirs
- Ecologists to make health authorities responsible for the principles of public hygiene
- Epidemiologists to outline surveillance strategies
- Media to inform about risks and prevention



Summary from pre-meeting questionnaire

Arjun Pandit, Hokkaido University

Kevin Chyi, D.V.M, APHIA Chinese Taipei


WOAH Interns

19 September 2024 Tokyo, Japan



VBD(s) concerned by Regional Members-1/2

Diseases of concerns



VBD(s) concerned by Regional Members-2/2

LSD, JE, BTV, WNF, Dengue fever, Babesiosis are of the most concerns,

- 1. Widespread in the region
- 2. Doing their best to prevent, eradicate or contain in the territory
- 3. Zoonotic diseases

<u>Anaplasmosis</u>	Epizootic hemorrhagic disease	Severe Fever with Thrombocytopenia
Theileriosis	Q fever	Syndrome(SFTS)
African horse sickness	Akabane disease	Hepatozoon
African swine fever	Crimean-Congo haemorrhagic fever	Chuzan virus
Trypanosomiasis	Malaria*	Chikungunya
Leishmaniosis	Mycoplasma haemocanis	Bovine ephemeral fever
Rift valley fever	Dirofilaria	Ehrlichia canis
	Schistosomiasis	Rickettsia felis

:Diseases listed in the Terrestrial code



Responses to VBD(s)-1/2

- Surveillance
 - Vector surveillance (mosquito, biting midge, stable fly, fly, tick...)
 - Active surveillance (LSD, JE, BTV, WNF, AHS, Akabane disease, RVF ...)
- Preventive measures
 - Vector control (Repellant, insecticide, vector trap...)
 - Biosecurity on farm
 - Vaccination (LSD, JE, Q-fever, Akabane disease...)
 - Contingency plan
- Response during a disease outbreak
 - Movement control (LSD, JE, AHS, ASF...)
 - Treatment (Q-fever, Surra, tick...)
 - Stamping out (LSD, AHS, ASF...)



Responses to VBD(s)-2/2

- Public awareness
 - Training and education
 - Communication (Using One Health approach. Conducting awareness campaigns to the general public)
- Diagnostic ability
 - Development of the detection method (diagnostic kit for detection Surra)
 - Diagnostic training




Impact of actions

- Successfully prevent or eradicate VBD (14)
 - Reduce the risk of exposure (11)
 - To regain VBD-free status (3)
- Diagnostic and Surveillance efficiency increased (8)
 - Enhanced diagnostic and surveillance ability (6)
 - Importance of early warning system (2)
- Vaccination is effective in controlling VBD (5)
 - Vaccination is an effective measure to combating VBD (4)
 - Make stockpiles of vaccines possible (1)
- Other impact
 - Strengthen awareness and education, data-sharing
 - Improved policy and strategies, established list of priority, identify the risk, enhanced biosecurity



Summary of challenges faced by members



Other problems: Awareness problems, under-reporting, and surveillance problems



Possible solutions to overcome the challenges

Capacity development

- Diagnostic to field staff
- Continued education
- Vector and vaccine development training

Coordination with partners

- Strengthen cross-border collaboration between partners
- Cost-sharing (PPP with development partners),
- Coordination from sub-national to International level


Surveillance facilitation

- **Data sharing and some innovations (**PCR on feral pig tonsils, chew ropes for monitoring tools for pigs: Australia),
- Country-level sustainable active surveillance



Collaboration with other sectors under One Health approach

OH status of members





Collaboration with other sectors under One Health approach

Multisectoral collaboration

- Shared surveillance information/Protocol/Publication/collaborative risk assessments (New Zealand)
- Multisectoral collaboration from the sub-national to the international level
- Co-writing of contingency plans (New Caledonia)

• Joint surveillance

- Joint surveillance of feral animals and other animals (Australia)
- Arbovirus surveillance (Japan)
- JE and wildlife disease surveillance (Malaysia)
- integrated surveillance (New Caledonia)



Possible actions to strengthen One Health approach

Multisectoral collaboration

- Data and Information Sharing
- Joint surveillance framework
- Multisectoral expert networking
- Joint research projects
- Collaborative preparedness resilience
- Zoonoses simulation exercises
- Joint capacity building

Regular stakeholder meeting

- Frequent meetings between stakeholders
- Creating platforms for knowledge-sharing
- Information sharing frameworks
- Regular resource funding.



Expectations for the VBDs workshop

• Experiences of members

- VBDs epidemiology in the climate change context
- Success stories and experience of members (Epizootic hemorrhagic diseases in Europe, Akabane disease and Blue Tongue in China and India)
- SFTS management
- Early warning systems
- Contingency plans of different members

• Information from experts on specific diseases

- Management strategy
- Latest global epidemiology of LSD, WNF, and AHS
- Cost-effective early warning system of VBDs.



Thank you

World Organisation for Animal Health WOAH Regional Workshop on Vector borne diseases in Asia and the Pacific Tokyo, Japan, 19 - 20 September 2024 09:10 - 09:30

Zoonotic and human related diseases and their control

Ken Maeda, Ph.D., D.V.M.

Director

Department of Veterinary Science

National Institute of Infectious Diseases (NIID)

Major emerging viral zoonosis in Japan

Date	Emerging viral diseases	Vector	Animals
Dec, 2012	First report of severe fever with thrombocytopenia syndrome (SFTS) in Japan	Tick	Many mammalians
Aug, 2014	Endemic of <mark>dengue fever</mark> in Tokyo after 69 years	Mosquito	Non-human primates (sylvatic type)
Jul, 2016	Tick-borne encephalitis after 23 years	Tick	Rodents, Wild animals
May, 2019	First discovery of <mark>Yezo virus</mark> in the world	Tick	Wild animals?
Nov, 2019	First report of <mark>B virus</mark> infection in Japan (2 cases)		Macaque
Jan, 2020	Pandemic of COVID-19 in Japan		Bat?
May, 2020	Rabies in Japan after 14 years		Dog, Bats
Jul, 2022	<mark>Mpox</mark> in Japan		Rodents etc.
Summer, 2022	Oz virus infection in Chiba	Tick	Wild animals


The first case of SFTS in Japan

- Patient:Female aged 50's without oversea travel
- Onset time and location: Autumn 2012, Yamaguchi prefecture
- Symptoms: Fever, general fatigue, vomiting, melena (bloody diarrhea)
- Laboratory findings: Leukopenia (400 /mm³) and Thrombocytopenia (8.9X10⁴ /mm³) in TBC;

Elevated AST, ALT, LDH, CK;

Extremely elevated ferritin in serum chemistry;


Hematuria and proteinuria in urinalysis; Hemophagocytosis with hypocellularity findings in bone marrow aspiration




Takahashi T, Maeda K, Suzuki T, Ishido A, Shigeoka T, Tominaga T, Kamei T, Honda M, Ninomiya D, Sakai T, Senba T, Kaneyuki S, Sakaguchi S, Satoh A, Hosokawa T, Kawabe Y, Kurihara S, Izumikawa K, Kohno S, Azuma T, Suemori K, Yasukawa M, Mizutani T, Omatsu T, Katayama Y, Miyahara M, Ijuin M, Doi K, Okuda M, Umeki K, Saito T, Fukushima K, Nakajima K, Yoshikawa T, Tani H, Fukushi S, Fukuma A, Ogata M, Shimojima M, Nakajima N, Nagata N, Katano H, Fukumoto H, Sato Y, Hasegawa H, Yamagishi T, Oishi K, Kurane I, Morikawa S, Saijo M. The first identification and retrospective study of Severe Fever with Thrombocytopenia Syndrome in Japan. J Infect Dis. 2014 Mar;209(6):816–27. doi: 10.1093/infdis/jit603. Epub 2013 Nov 14. PMID: 24231186; PMCID: PMC7107388.

Clinical symptoms in human patients


Recovery Death



Distribution and age of SFTS patients in Japan



Transmission cycle of SFTSV



Clinical symptoms in SFTS cats



No. of Positive	Ratio
/No. of Total	Πάτιο

Low activity Anorexia	97/97	100%
Vomiting	44/95	46%
Diarrhea	5/95	5%
Jaundice	43/43	100%
Death	41/69	59%

First SFTS dog and symptoms in SFTS dogs



- June, 2017
- Mix
- Spayed female
- 4 years old
- Every year 6 combination vaccine and rabies vaccine
- Heartworm and tick preventives


Clinical findings in seven SFTS dogs

Clinical findings	Number of dogs with abnormal values (%)		
Anorexia and less activity	7 (100%)		
Vomit	2 (29%)		
Loose stool	2 (29%)		
Dead	3 (43%)		
Fever (>39°C)	7(100%)		
Leukocytopenia (<6,000/µl)	7(100%)		
Thrombocytopenia (<200,000/µl)	7 (100%)		
Tick parasite	5 (71%)		


Owner of this SFTS dog was also infected with SFTSV without tick-bite

Oshima H et al., Jpn J Infect Dis. 2022 Jul 22;75(4):423-426. Ishijima K et al., Viruses. 2022 Sep 4;14(9):1963


Number of SFTS cases in animals and humans



Transmission from cats and dogs to human



SFTSV transmission from a cat to humans




Yamanaka A et al., Emerg Infect Dis. 2020 Dec;26(12):2994-2998

Direct transmission from animals to human

Jun, 2017	Dog⇒Owner
Aug, 2018	Cat⇒Veterinarian and nurse
Oct, 2018	Cats⇒Veterinarian
Oct, 2018	Cat⇒Owner(Dead)
May, 2019	Cat bite⇒Owner
Aug, 2019	Cat⇒Owner
Nov, 2019	Cat⇒Veterinarian
Mar, 2020	Cat⇒Owner
Jun, 2020	Cat⇒Veterinarian
Feb, 2021	Cat⇒Veterinarian
Feb, 2021	Cat⇒Veterinarian
Jun, 2021	Cat⇒Veterinarian

Distribution of SFTSV in Asian countries



Ongkittikul S et al. *Bangkok Med J* 16, 2 (Sep. 2020), 204. Zohaib A et al. Emerg Infect Dis. 2020 Jul;26(7):1513-1516. Kirino Y et al. J Infect Chemother. 2022 Jun;28(6):753-756.

Prevalence of SFTSV infection in Thai dogs


		ELISA(OD>0.129)		FRNT ₅₀ (\geq 1:10)		
Province	District	No. of	No. of	No. of	No. of	Minimum
		Examined Dogs	Positive Dogs	Examined Dogs	Positive Dogs	Positive Ratio
Prachinburi		17	1	1	0	0.0%
Bangkok		143	12	12	6	4.2%
Chachoengsao		18	2	2	2	11.1%
Samutprakan		81	19	16	10	12.3%
Rayong		14	2	2	1	7.1%
Chonburi	Mueang Chonburi	27	6	6	3	11.1%
	Banglamung	56	5	5	3	5.4%
	Sattahip	95	56	52	50	52.6%
	Pattaya city	7	3	2	1	14.3%
Total		458	106	98	76	16.6%
		100 KUVL-49 Japan Kagoshima Cat 0 KY789439.1 CB1 South Korea Human 100 KY362332.1 JS2015-69 China Human 100 KR230791.1 JS2011-69 China Human 90 KR230805.1 JS2014-H.longicornis-01 China H.longicornis 93 ON840548.1 BK1861 Thailand Human 100 KR230800.1 JS2014-16 China Human 93 ON8405548.1 BK1861 Thailand Human 100 KR230800.1 JS2014-16 China Human 0 ON840550.1 BK3247 Thailand Human 100 KU664012.1 HB147/China/2012 Human China 100 KU664012.1 HB147/China/2012 Human China 67 MK513904.1 HB2015-09 China Human 67 MK513904.1 HB2017-17 China Human 96 KY933681.1 HB2014-31 China Human			Japan China Korea	

Summary of SFTS infection

- SFTS is a tick-borne disease
- SFTSV causes severe disease in human
- CFR in human is 27% in Japan
- SFTSV can infect to many animals
- SFTSV causes lethal disease in cats and the CFR is 60%
- SFTSV can transmit from diseased animals to humans
- Pet owners and veterinarians are at high risk of SFTSV infection
- Veterinarians should protect themselves by PPE (glove, mask, gown, goggles, face shield)


Characterization of Oz virus


, Oz virus belongs to *Paramyxoviridae*




Pleomorphic viral particles, including both filamentous and round particles, budded directly from the plasma membrane of infected cells

Oz virus can grow well in mammalian cell lines





Oz virus can kill suckling mice



Ejiri H, Lim CK, Isawa H, Fujita R, Murota K, Sato T, Kobayashi D, Kan M, Hattori M, Kimura T, Yamaguchi Y, Takayama-Ito M, Horiya M, Posadas-Herrera G, Minami S, Kuwata R, Shimoda H, Maeda K, Katayama Y, Mizutani T, Saijo M, Kaku K, Shinomiya H, Sawabe K. Characterization of a novel thogotovirus isolated from Amblyomma testudinarium ticks in Ehime, Japan: A significant phylogenetic relationship to Bourbon virus. Virus Res. 2018 Apr 2;249:57-65.

Oz virus is similar to Bourbon virus in U.S.A

Oz virus infects many mammalian species


Creater	Year	VN titer							
Species		<1:10	1:10	1:20	1:40	1:80	1:160	1:320	Ratio
Human	2015	22	0	0	1	1	0	0	8.3%
Monkey	2012- 2019	91	0	4	5	4	9	7	24.2%
Wild boar	2013- 2015	49	2	12	10	15	20	16	60.5%
Sika deer	2014– 2015	20	5	8	11	12	13	7	73.7%

Tran NTB, Shimoda H, Ishijima K, Yonemitsu K, Minami S; Supriyono; Kuroda Y, Tatemoto K, Mendoza MV, Kuwata R, Takano A, Muto M, Sawabe K, Isawa H, Hayasaka D, Maeda K. Zoonotic Infection with Oz Virus, a Novel Thogotovirus. Emerg Infect Dis. 2022 Feb;28(2):436-439. doi: 10.3201/eid2802.211270. PMID: 35075999; PMCID: PMC8798690.

The first patient with Oz virus infection

Date: early summer of 2022

- Patient: female in her 70s, resident of Ibaraki Prefecture, underlying hypertension and dyslipidemia, no history of overseas travel
- Symptoms: fatigue, loss of appetite, vomiting, joint pain, and a fever of 39 °C, ultimately resulting in viral myocarditis and death




- Blood tests: thrombocytopenia (66,000/μL), liver disorder, renal disorder, high serum markers of inflammation (CRP 22.82 mg/dL), high CK (2049 U/L, CK-MB 14 IU/L), high LDH (671 U/L), high ferritin (10729 ng/mL), simple CT normal.
- On hospitalization: Engorged ticks in the right inguinal region. No rickettsia or SFTS, blood culture negative.
- During hospitalization: Pacemaker implanted due to atrioventricular block. Various tests suspected myocarditis. The pacemaker was removed after approximately 10 days, when the patient's pulse stabilized. On the 20th day of hospitalization, consciousness disorder and multiple cerebral infarctions were observed, and anticoagulation therapy was started. The patient had persistent fever, but thoracoabdominal pelvic contrast CT could not point out any obvious foci or organ enlargement that could be the source of the fever.

IASR Vol.44 (7): p109-111:2023

Catalogue of tick-borne viruses in Japan

Viruses	Classification	Isolation	Tick	Animal	Human	Disease
SFTS virus	Bunyavirales	0	0	0	0	SFTS
Yezo virus	Bunyavirales	0	0	0	0	Like SFTS
Iwanai Valley virus	Bunyavirales	0	0			
Ama virus	Bunyavirales	0	0			
Tofla virus	Bunyavirales	0	0			
Toyo virus	Bunyavirales		0			
Kabuto Mountain virus	Bunyavirales	0	0	0	0	?
Okutama tick virus	Bunyavirales		0			
Mukawa virus	Bunyavirales	0	0	0		
Soft tick bunyavirus	Bunyavirales	0	0			
Kuriyama virus	Bunyavirales	0	0			
Tick-borne encephalitis virus	Flaviviridae	0	0	0	0	Encephalitis
Yamaguchi virus	Flaviviridae		0	0		
Negishi virus	Flaviviridae	0		_	0	Encephalitis
Saruyama virus	Flaviviridae		0	0		
Ohshima virus	Orthomyxoviridae		0			
Thogoto virus	Orthomyxoviridae	0	0	0	?	
Oz virus	Orthomyxoviridae	0	0	0	0	Myocarditis
Tarumizu tick virus	Reoviridae	0	0	0		
Muko virus	Reoviridae	0	0	0		
Kemerovo virus	Reoviridae	0	0	?	?	
Sekira virus	Nyamiviridae		0			
H. Flava Ifla virus	Iflaviridae		0			

One Health approach for tick-borne diseases



Acknowledgements



National Institute of Infectious Diseases

Department of Veterinary Science Department of Virology I Department of Pathology Department of Medical Entomology Research Center for Influenza and Respiratory Viruses Research Center for Biosafety, Laboratory Animal and Pathogen Bank Yamaguchi University Kagoshima University Nagasaki University Okayama Science University Miyazaki University Tokyo University of Agriculture and Technology The University of Tokyo Hokkaido University Hiroshima Veterinary Medical Association

Veterinary Professionals throughout Japan








Ministry of the Environment

Climate change, wildlife and zoonoses: HPAIV as a model case



Koichi GOKA and Manabu Onuma National Institute for Environmental Studies

Wild Ducks as Long-Distance Vectors of Highly Pathogenic Avian Influenza Virus (H5N1)

Juthatip Keawcharoen,* Debby van Riel,* Geert van Amerongen,* Theo Bestebroer,* Walter E. Beyer,* Rob van Lavieren,* Albert D.M.E. Osterhaus,* Ron A.M. Fouchier,* and Thijs Kuiken*

Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 4, April 2008


Comment

https://doi.org/10.1038/s41564-023-01538-0


Climate change impacts on bird migration and highly pathogenic avian influenza

Diann J. Prosser, Claire S. Teitelbaum, Shenglai Yin, Nichola J. Hill & Xiangming Xiao

Check for updates




Animals infected with highly pathogenic avian influenza viruses




Nationwide AIV surveillance in Japan

Wild ducks (wintering in Japan) (October – March)




Shorebird (The East-Asian Australasian Flyway) (July – September)



Funded by MOE


Funded by NIES

Nationwide AIV surveillance using fecal samples of Wild ducks (2008-2020)





52 locations (Oct.-May)



 \approx 3,000 tubes /season


5 feces/tube



Temporal change of AIV prevalence (2008-2018)

RT-LAMP positive rate in fecal samples (%)

Onuma M. Unpublished data



Time series changes in positivity rates (by region)




Autum migration (Oct.~Nov.) Wintering (Dec.~Feb.)

Spring migration (Mar.~May)

F


Regions with positivity rates above the national average

Result of species identification by DNA barcoding




Nationwide AIV surveillance in Japan

Wild ducks (wintering in Japan) (October – March)




Shorebird (The East-Asian Australasian Flyway) (July – September)



Funded by MOE

Funded by NIES

Nationwide AIV surveillance in shorebirds









Result: AIV detection (by RT-LAMP)

	2006	*2007	*2008	2009	*2010	Total
Numbe	340	289	210	329	579	1,747
Þositive (%)	0	0	0	0	1 (0.2)	1 (0.1)


* HPAIV positive cases in wild birds



Lesser Sand Plover (*Charadrius mongolus*)

Captured at Komuke lake in September 3rd, 2010

Result: Subtyping (by sequencing)



HA: H10 (1,686 bp) A/mallard/Korea/1242/2010(H10N6) (99% identity)

NA: N7 (1,416 bp) A/common teal/Hong Kong/ MPM1740/2011(H7N7) (99% identity)

Antibody prevalence of avian influenza virus in shorebirds (2017~)




Ruddy Turnstone (*Arenaria interpres*) 34.8% (8/23)



Whimbrel (*Numenius phaeopus*) 36.4% (4/11)


Nationwide AIV surveillance in Japan

Wild ducks (wintering in Japan) (October – March)






Shorebird (The East-Asian Australasian Flyway) (July – September)



Identification of high-risk regions








Autum migration (Oct. ~Nov.) Wintering (Dec.~Feb.)

Spring migration (Mar.~May)

Environmental niche modelling




https://www.unil.ch/webdav/site/idyst/shared/modeling.png


Method

Program: MaxEnt version 3.3.3e, Phillips et al., 2006 (The maximum entropy approach)

Data: Locations of LPAIV and HPAIV 2004-2011



Risk map for avian influenza in wild birds




Contributions of independent variables to the model.

Independent variables	<u>Contribution</u>				
Dabbling duck population	49.4 ± 5.5				
Urban area	12.5 ± 3.5				
Altitude	8.2 ± 2.3				
Diving duck population	3.5 ± 3.5				
Lake area 2.2 ± 1	.5				
Farmland area	0.9 ± 1.2				
Poultry density	0.5 ± 0.5				
Mean precipitation in winter	0.3 ± 1.0				
Min temperature in winter	0.1 ± 0.1				
Distance to lakes	0.0 ± 0.0				
Sum of spatial filters 22.5 \pm 5.6					


Sum of spatial filters 22.5 \pm 5.6

(Moriguchi et. al., 2013)


Risk map of avian influenza in raptors



Risk map of avian influenza in raptors




Climate change impacts on bird migration and highly pathogenic avian influenza (Prosser et al. 2023)



doi: 10.1038/s41564-023-01538-0.


" long-distance migratory species tend **to track their niche** and select largely **similar environments through seasons**" Zurell et al. (2018, J. Biogeog.)

"Is it possible to estimate 'when' and 'where' migratory birds are using an ecological niche model with seasonal climate data?"



Ikegami et al. unpublish data

Animals infected with highly pathogenic avian influenza viruses



Mass mortality event of marine mammals in Russia (Summer 2023)

